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Introduction 
Therapeutic approaches for cancer treatment have been evolving while 
still struggling with several limitations. Non-specificity is the underlying 
reason for unwanted effects of chemotherapeutic agents on normal cells 
(Grivennikov S., 2010). One of the main downside is the multi-drug 
resistance (MDR) of cancer cells to chemotherapeutic agents (Xue X. et al., 
2012). Chemo-resistance is a multifactorial process directly linked to an 
over-expression or suppression of certain molecular pathways with 
consequent treatment failure. Currently applied strategies to manage 
chemo-resistant cancers in clinical oncology involve re-challenging the 
disease with novel formulations of conventional chemotherapeutics. In 
some cases, the development of formulations able to change the drug 
distribution and to increase drug accumulation into the tumor tissue/cells 
can allow to re-consider “old drugs” that can be transformed in new and 
powerful anticancer agents (De Rosa G. et al., 2013). Furthermore, the 
combination of chemotherapeutics and agents with selective knockdown of 
genes responsible for altering the susceptibility of these drugs, such as 
small interfering RNA (siRNA), may lead to a synergistic effect in 
response to the treatments. However, the very rapid degradation of the 
nucleic acids in biological environment, together with their low 
bioavailability hampers the development of therapeutic strategies based 
DNA or RNA oligonucleotide. 
 Among the different formulative approaches, the use of 
nanotechnologies to deliver drugs in cancer therapy is certainly receiving a 
growing attention. The number of papers published in 2013 on this topic is 
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of about ten times higher if we compare the number of papers published in 
one year a decade before (Figure 1).  
 
Figure 1. Number of publications in nanotechnology aerea in the last 10 years (data 
from Medline). 
Nanoparticles (NPs) for cancer therapeutics are being introduced in 
order to overcome several limitations of conventional small-molecule 
chemotherapeutics and to increase treatment efficacy. Over the past 
decades, different “first-generation” therapeutic NP-based products are on 
the market. Liposomes, the first NP platform, have widely demonstrated a 
significant improvement of the therapeutic benefit of clinically validated 
drugs by enhancing drug tolerability and/or efficacy. The introduction of 
liposomes containing antracyclines in clinic, firstly Daunoxome and then 
Doxil/Caelyx/Lipodox, significantly changed the landscape of cancer 
treatment. The encapsulation of doxorubicin in liposome achieved a 
significant decrease of the cardiotoxicity and enhance the efficacy of 
doxorubicin even in drug-resistant tumors. Later on, Abraxane and 
Genexol-PM, respectively albumin NPs and polymeric micelles for the 
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delivery of Paclitaxel (PXL), were the following classes of therapeutic 
nanomedicine to be commercialized. Both technologies,  when compared to 
standard PXL (Taxol), demonstrated significantly higher tumor response 
rates, longer times to tumor progression and avoided the concomitant use 
of the toxic Cremophore (Gradishar W. J. et al., 2005).  
 
Figure 2. Historical timeline of NPs based products on the  market. 
In the last decade, the research is moving on the design of 
“multifunctional” NPs, aimed at increasing the safe and the effectiveness of 
NPs. Paul Ehrlich, the “father of chemotherapy”, approximaly a century 
ago introduced the concept of a “magic bullet” rifering to a drug that can 
selectively attach diseased cells avoiding health cells (Strebhardt K. et al., 
2008). Several strategies can be approached to allow a drug to reach a 
specific target. Among all, the conjugation of targeting ligands to the 
surface of the NPs have been proposed in order to increase the selectivity 
of the NPs towards cancer cells also increasing the intracellular uptake 
(Gary-Bobo M. et al., 2013; Crommelin D.J. et al., 2013; Lammers T., 
2008). In addition, NPs can be modified for targeting specifically not only 
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cancer cells but also tumors surrounding impermeable biological barriers 
such as the blood brain barrier (BBB). Chemotherapy for brain tumors has 
been of limited value because of the low transport ratio of drugs across the 
BBB.  Besides the physiological barrier restriction, the inability of certain 
drugs to cross the BBB is also caused by MDR proteins over-expressed on 
this endotehelial barrier, with consequent high drug efflux from the brain 
(Demeule M. et al., 2001). A powerful approach to treat brain disorders 
could be to combine in one nanosystem tumor targeting strategy, gene 
terapy and chemotherapy.  Lui et al., developed transferrin targeted-
dendrimers co-loaded with doxorubicin and TRAIL in the hope of 
developing an effective treatment for glioma. This combination of 
treatments demonstrated an increased accumulation of NPs in tumor site 
together with an enhancement of survival of animals and reduction of 
unwanted toxicities (Liu S. et al., 2012). 
The ability of certain NPs to co-encapsulate multiple therapeutics have 
been successful in reversing the MDR in cancer. In the recent years, several 
types of NPs co-loaded with multiple chemotherapeutic agents have been 
well characterized and have demonstrated improved anti-cancer activity. 
Yadav S. et al., (2009) demonstrated enhanced PXL cytotoxicity in a 
resistant SKOV3 cell lines by using polymeric NPs co-loaded with PXL 
and a siRNA silencing MDR-1. Wu et al., formulated a transferrin 
conjugated liposomes containing doxorubicin and verapamil (a P-gp 
inhibitor). They showed enhanced cytotoxicity by overcoming the P-gp-
mediated MDR in resistant K562 cells (Wu J. et al., 2007). 
Despite the success of these strategies suggested by the introduction of 
nanotechnology-based products on the market, the wide medical 
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applications of these systems has been hindered due to the narrow range of 
active molecules (e.g., broad range of small molecules, proteins, and 
nucleic acids) clinically validated in “nanotechnological form”. This could 
be correlated to different reasons, such as doubtful superiority of some 
formulations, e.g. Doxil, in terms of antitumor efficacy compared to the 
free drug. Moreover, even when the results obtained from preclinical 
experiments encourage to move to the clinical phase of the study, the scale-
up as well as the preparation of these products in a Good Manufacturing 
Practice quality is difficult to achieve.  
Recently, to address these problems, studies have been focused on the 
possibility to develop self-assembling nanosystems to overcome stability 
and scale-up issues (Doll T.A. et al., 2013; Jeong J.H. et al., 2011; 
Torchilin V.P., 2007; Chaturvedi K. et al., 2011). Interestingly, a product 
consisting in a self-assembling nanocarrier for siRNA delivery arrived in 
clinic and concluded the phase I of evaluation (Davis M.E., 2009).  
It can be expected that, in the next future, by using the “self-assembling 
approach” new nanotechnology-based products will get clinical phase of 
study more easily. On the light of these considerations, in order to have a 
concreate impact in the treatment of cancer and on the health of patients, a 
more detailed study of the potentialities of the “self-assembling approach”, 
i.e. to overcome MDR and/or the BBB, should be a priority. 
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Objective 
The main objective of the research activity was the development of new 
self-assembling formulations based on nanotechnology for the delivery of 
active agents in tumors. The first part of the work, was carried out in the 
laboratories of pharmaceutical technology of the Department of Pharmacy, 
Università degli Studi di Napoli Federico II, while the second part was 
done at the Department of Pharmaceutical Sciences, Northeastern 
University of Boston (USA). The research activity was articulated on two 
main projects summarized as follows: 
1. Design of self-assembling NPs actively functionalized with human 
transferrin for the delivery of zoledronic acid in brain tumors.  
2. Development of multifunctional polymeric micelles for the co-delivery 
of an anti-survivin siRNA and Paclitaxel for the reversal of drug resistance 
in ovarian cancer. 
In both projects, we proposed and developed particularly promising 
approaches which combined four crucial elements in one “ultimate NP”: 
1. Use of simple and reproducible methods to prepare the formulations 
in order to develop NPs easily to scale-up; 
2. Excellent physical characteristics of the NPs, in terms of 
incorporation efficiency of the different agents, and size suitable to be 
systemically used for tumor targeting; 
3. Significant inhibition of the cell growth and marked biological 
effects in different cancer cells by using the developed NPs, superior to that 
obtained with free drugs;  
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4.  Efficacy of the developed NPs encapsulating the active molecules on the 
inhibition of the tumor growth of xenograft animal models of different 
tumors. 
 
 
Chapter 1 
 
 
“Transferrin targeted-self-assembling nanoparticles 
containing zoledronic acid: a new strategy for the 
treatment of brain tumors” 
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Summary 
Glioblastoma multiform (GBM) is the most common and aggressive 
primary malignant brain tumor. Despite the progress in the areas of 
radiotherapy and chemotherapy, GBM remains a very difficult cancer to 
treat. Here, to open a new scenario for the treatment of GBM, we have 
proposed a new strategy for the use of zoledronic acid (ZOL) in brain 
tumors. ZOL, a third generation bisphosphonate, is a breakthrough for the 
treatment of bone diseases.  In the past decade, several studies have 
reported a potent anti-cancer activity of ZOL in a wide range of cancer cell 
lines. Earlier, we have demonstrated, in different animal models of cancer, 
a mighty anti-tumor activity by encapsulating ZOL in nanoparticles (NPs). 
Here, in order to improve the target of ZOL to GBM tumor cells and to 
allow the NPs to overcome the blood brain barrier (BBB), we have 
designed transferrin (Tf)-targeted self-assembled NPs incorporating ZOL, 
here named Tf-PLCaPZ NPs. The ability of the developed 
nanopreparations to bind Tf receptors on cells, to be uptaken by GBM 
tumour cells was investigated by FACS and confocal microscopy analysis 
in  LN229, U373MG and U87MG, GBM cell lines. Then, in the same cell 
lines, we have evaluated the effect of the functionalized NPs on the cell 
growth inhibition by MTT assay. Confocal microscopy and FACS analysis 
showed that in LN229 cells, GBM expressing the highest degree of Tf-
receptor, a significant uptake of Tf-PLCaPZ NPs was achieved. 
Interestingly, the cell penetration of Tf-PLCaPZ NPs was much higher than 
the one observed after treatment with no functionalized NPs (PLCaPZ 
NPs).  Moreover, Tf-PLCaPZ NPs induced an oligodendrocytic 
differentiation in this cell line. The potentiation of anti-proliferative activity 
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of Tf-PLCaPZ NPs was equal (LN229) or less (U373MG and U87MG) if 
compared to PLCaPZ NPs and was correlated with Tf receptor expression 
on tumour cells. In a second step, we have investigated the potential of a 
combined therapy of temozolomide (TMZ), a gold standard for the 
treatment of GBM, and Tf-PLCaPZ NPs. The results revealed that, in 
LN229 cells the sequential therapy of TMZ and Tf-PLCaPZ NPs leading to 
superior therapeutic activity compared to their single administration.  
Finally, we have evaluated the activity of Tf-PLCaPZ NPs in an 
orthotropic model of  nude mice xenografted with U373-MG GBM cells. 
Interestingly, the treatment with Tf-PLCaPZ NPs elicited the highest anti-
cancer activity compared to all the other treatment groups.  
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Introduction 
GBM are highly aggressive brain tumors with poor clinical outcome. 
Despite a broad range of new and more specific treatment strategies, the 
therapy of GBM remains challenging and tumors relapse in all the cases. 
The main limit of conventional chemotherapy in the treatment of brain 
tumors is the inability of most of the anti-cancer agents, when 
intravenously administrated, to reach effective concentration within the 
brain parenchyma. The  BBB protects brain from toxicological injuries but, 
at the same time, makes impossible the crossing of the most of therapeutic 
agents in the brain. Only highly lipophilic molecules can passively diffuse 
through BBB to reach central nervous system (CNS).  
On the light of these considerations, it has become extremely important 
to develop suitable dosage form capable to sensitize brain tumors to 
conventional therapies (Chinot O.L. et al., 2013; Zhu J.J. et al., 2013). 
Moreover, the potential to use new agents, such as ZOL, should be 
investigated. 
ZOL belongs to the nitrogen containing bisphosphonates (NBPs), agents 
of choice for  the treatment of bone metastases. ZOL inhibits the farnesyl 
pirophosphate synthase (FPPS), the upstream enzyme involved in the 
cholesterol synthesis chain, (Aparicio A. et al., 1998; Senaratne S.G. et al., 
2000; Lee M.V. et al., 2001; Schafer W.R. et al., 1992), with consequent 
inhibition of cell proliferation, differentiation,  adhesion and tumorogenesis 
(Caraglia M. et al., 2006). Due to these pharmacodynamic effects, ZOL has 
widely demonstrated a direct anti-proliferative action on human tumor cells 
in vitro (Caraglia M. et al., 2004). Unfortunately, ZOL has a very short 
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plasma half-life and tends to accumulate in the bone, which results in far 
below therapeutically effective levels that reach tumor tissues (Chen T. et 
al., 2002; Skerjanec A. et al., 2003). Therefore, new approaches aimed at 
increasing ZOL plasma half-life and achieve effective concentrations of 
ZOL in different districts, such as tumors, must be designed (Caraglia M. et 
al., 2006). To address this problem, previously we proposed a new 
nanopreparation for the delivery of ZOL in solid tumors. In particular, NPs 
made by a mixture of calcium phosphate NPs (CaP NPs) and PEGylated 
cationic liposomes were developed by using self-assembling processes. The 
developed formulation exhibit optimal physical characteristics together 
with the possibility to  prepare the NPs immediately before use, 
overcoming problems of stability during the storage which often hampers 
the scale-up of many promising drug delivery systems (Salzano G. et al., 
2011). In addition, in in vivo model of prostate adenocarcinoma, a strong 
and significant inhibition of the tumor growth was demonstrated (Marra M. 
et al., 2012).  
In this study, in order to investigate the potential of ZOL also in the 
treatment of aggressive GBM tumors, we upgraded the previous developed 
NPs by introducing human Tf on the surface. The introduction of specific 
ligands on the surface of NPs offers the chance of improving the efficacy 
and specificity of therapeutics in certain diseases as well as to enhance the 
access of the NPs to impermeable barriers, such as the BBB. (Patel M.M. et 
al., 2009; Korfel A. et al., 2007).  
Here, we described the development and the physical characterization of 
Tf-PLCaPZ NPs, in terms of size distributions and surface proprieties of 
the NPs after introduction of Tf.  Then, we investigated the ability of the 
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Tf-PLCaPZ NPs to bind Tf receptors that are over-expressed on GBM 
cells. Besides, the hemolytic activity of the nanopreparations was evaluated 
on human blood cells. The effect of Tf-PLCaPZ NPs on the growth 
inhibition of GBM cells was studied and compared to non-targeted 
PLCaPZ NPs. In addition, in the same cells, we investigated  the 
mechanisms on the cell death induced by Tf-PLCaPZ NPs and the ability 
of the developed NPs to potentiate the anti-proliferative activity of TMZ, 
an anti-cancer agent conventionally used for the treatment of GBM 
patients. Finally, the anti-tumoral effects of Tf-PLCaPZ NPs, on 
intracranially human GBM xenografts, have been evaluated.  
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Materials and methods 
Materials 
Unless otherwise stated, all chemicals were from Sigma-Aldrich (Saint 
Louis, MO, USA). 1,2-dioleoyl-3-trimethylammonium-propane chloride 
(DOTAP) and 1,2-diacyl-sn-glycero-3-phosphoethanolamine-N-
[methoxy(polyethylene-glycol)-2000] (DSPE-PEG2000) were obtained from 
Lipoid GmbH (Cam, Switzerland). 23-(dipyrrometheneboron difluoride)-
24-norcholesterol (CHOL BODIPY) was purchased from Avanti Polar 
Lipids. RPMI 1640, DMEM and FBS were purchased from 
FlowLaboratories (Milan, Italy). Tissue culture plasticware was from 
Becton Dickinson (Lincoln Park, NJ, USA). Rabbit antisera raised against 
α-tubulin and CD71 were purchased from Santa Cruz Biotechnology (Santa 
Cruz, CA, USA). ZOL was kindly provided by Novartis (Novartis, Basilea, 
Switzerland).  
Preparation of self-assembled NPs encapsulating ZOL  
Self-assembly NPs encapsulating ZOL, so-called PLCaPZ NPs, were 
prepared starting from a ZOL aqueous solution, calcium/phosphate 
nanoparticles (CaP NPs) and PEGylated cationic liposomes.  
CaP NPs were prepared as follows. An aqueous solution of calcium 
chloridre (18 mM) was added,  dropwise and under magnetic stirring, to an 
aqueous solution on dibasic hydrogen phosphate (10.8 mM). The pH of 
both solutions was adjusted beforehand to 9.5 with NaOH. The resulting 
suspension was filtered through a 0.22 µm filter (0.22 µm  pore size, 
polycarbonate filters, MF-Millipore, Microglass Heim, Italy) and then 
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stored at 4°C before use. To complex ZOL with CaP-NPs (CaPZ-NPs), an 
aqueous solution containing the amino-bisphosphonate (50 mg/ml) was 
mixed with the CaP NP dispersion, at a volume ratio of 50:1, respectively.  
PEGylated cationic liposomes consisting of  DOTAP/chol/DSPE-PEG2000 
(1:1:0.5) were prepared by hydration of a thin lipid film followed by 
extrusion. Briefly, the lipid mixture were dissolved in 1 ml of a mixture 
chloroform/methanol (2:1 v/v), the resulting solution was added to a 50 ml 
round-bottom flask, and the solvent was removed under reduced pressure 
by a rotary evaporator (Laborota 4010 digital, Heidolph, Schwabach, 
Germany) under nitrogen atmosphere. Then, the lipid film was hydrated 
with 1 ml of 0.22 µm filtered distilled water and the resulting suspension 
was gently mixed in the presence of glass beads until the lipid layer was 
removed from the glass wall, after that the flask was left at room 
temperature for still 2 h. The  liposome suspension was then extruded using 
a thermobarrel extruder system (Northern Lipids Inc., Vancouver, BC, 
Canada) passing repeatedly the suspension under nitrogen through 
polycarbonate membranes with decreasing pore sizes from 400 to 100 nm 
(Nucleopore Track Membrane 25 mm, Whatman, Brentford, UK). After 
preparation, liposomes were stored at 4°C. Each formulation was prepared 
in triplicate.   
Equal volumes of suspensions containing DOTAP/chol/DSPE-PEG2000 
liposomes and CaPZ NPs, respectively, were mixed in a glass tube and the 
resulting dispersion was allowed to stand at room temperature for 10 min 
(PLCaPZ NPs).  In particular,  500 μl of CaPZ NPs were added dropwise to 
500 μl of  DOTAP/chol/DSPE-PEG2000  in a glass tube. 
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Preparation of self-assembled NPs encapsulating ZOL functionalized 
with human Transferrin  
Tf-modified PLCaPZ NPs were prepared as follows. In a first step, 
PEGylated cationic liposomes consisting of DOTAP/chol/DSPE-PEG2000 
(1:1:0.5 weight ratio) were prepared by hydration of a thin lipid film as 
reported above. In a second step, pre-formed PEGylated cationic liposomes 
were mixed with human Tf (10 mg/ml in phosphate buffer at pH 7.4) at a 
volume ratio of 1:1, at room temperature for 15 min, obtaining the so-
called Tf-PEGylated cationic liposomes. Separately, CaP NPs containing 
ZOL were prepared as reported above. (Salzano G. et al., 2011). Finally, 
Tf-PLCaPZ NPs were obtained by mixing Tf-PEGylated cationic 
liposomes complex with CaPZ NPs, at a volume ratio of 1:0.5,  at room 
temperature for 15 min. Plain Tf-modified NPs (Tf-PLCaP NPs), ZOL-
encapsulating NPs without Tf (PLCaPZ NPs) and plain PLCaP NPs were 
prepared similarly. Each formulation was prepared in triplicate. For intra-
cellular penetration studies, fluorescently labeled NPs containing 0.1% 
(w/w) of CHOL BODIPY were prepared similarly by adding the 
fluorescent cholesterol in the lipid mixture of DOTAP/chol/DSPE-PEG2000  
during the liposomes preparation.   
Characterization of PLCaPZ NPs and Tf-PLCaPZ NPs 
The mean diameter of NPs was determined at 20°C by photon correlation 
spectroscopy (PCS) (N5, Beckman Coulter, Miami, USA). Each sample 
was diluted in deionizer/filtered water (0.22 µm  pore size, polycarbonate 
filters, MF-Millipore, Microglass Heim, Italy) and analyzed with detector 
at 90° angle. As measure of the particle size distribution, polydispersity 
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index (P.I.) was used. For each batch, mean diameter and size distribution 
were the mean of three measures. For each formulation, the mean diameter 
and P.I. were calculated as the mean of three different batches. The zeta-
potential (ζ) of the NPs surface was measured in water by means of a 
Zetasizer Nano Z (Malvern, UK). Data of ζ were collected as the average 
of 20 measurements. ZOL analysis was carried out by reverse phase high 
performance liquid chromatography (RP-HPLC) as previously reported 
(Salzano G. et al., 2011). The incorporation efficiency of ZOL in Tf-
PLCaPZ NPs was determined as follows: 1 ml of NPs dispersion was 
ultracentifugated (Optima Max E, Beckman Coulter, USA) at 80.000 rpm 
at 4°C for 40 min. Supernatant was carefully removed and analyzed to 
determine un-incorporated ZOL concentration by RP-HPLC. The results 
have been expressed as complexation efficiency, calculated as the ratio 
between the amount of ZOL present in the supernatant and the amount of 
ZOL theoretical loaded. 
Hemolysis assay 
Hemolysis assay was performed on fresh human blood as previously 
reported by Cheng C. et al. (2008) with slight modifications. The 
erythrocytes were collected by centrifugation at 2000 rpm for 15 min, and 
then washed three times with phosphate buffered saline (PBS) buffer at pH 
7.4. The stock dispersion was prepared by mixing 3 mL of centrifuged 
erythrocytes into 11 mL of PBS. Then, 100l of stock dispersion were 
added to 1 mL of NPs dispersions, prepared as reported above and 
incubated for 4 h at 37°C under slightly agitation. The percentage of 
hemolysis was determined by UV–vis analysis of the supernatant at 541 nm 
absorbance after centrifugation at 13,000 rpm for 15 min. Plain Tf-PLCaP 
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NP, PLCaPZ NP without Tf, plain Tf-PLCaP NP and ZOL free at a final 
concentration of 20 g were used as controls.  One milliliter of PBS was 
used as the negative control with 0% hemolysis, and 1 mL of deionized 
water was used as the positive control with 100% hemolysis. All hemolysis 
data were calculated using the following formula:  
Hemolysis % = (Abs-Abs0)/(Abs100-Abs0)*100 
Cell lines, protein extraction and western blotting 
Tf receptor (CD71) was evaluated in three different cell lines of human 
GBM, LN229, U87 MG and U373 MG by Western Blotting method. GBM 
cell lines were provided by Dr. C. Leonetti (Department of Experimental 
Oncology, Regina Elena National Cancer Institute IRCCS - Rome) and 
were grown in medium as suggested by ATCC in a humidified incubator 
containing 5% CO2 at 37°C. Cell cultures were washed twice with ice-cold 
PBS/BSA, scraped, and centrifuged for 30 min at 4°C in 1 ml of lysis 
buffer (1% Triton, 0.5% sodium deoxycholate, 0.1M NaCl, 1mM EDTA, 
pH 7.5, 10mM Na2HPO4, pH 7.4, 10mM PMSF, 25mM benzamidin, 1mM 
leupeptin, 0.025 U/ml aprotinin). Equal amounts of cell proteins, assessed 
by Lowry assay using bovine serum albumin as standard, were separated 
by SDS–PAGE. The proteins on the gels were electrotransferred to 
nitrocellulose and reacted with the different antibodies as previously shown 
(Marra M. et al., 2009). 
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Analysis of NPs intracellular distribution by FACS and confocal 
microscopy 
A BD FACS Calibur fluorescent-activated flow cytometer and the BD 
CellQuest software (BD Biosciences) were used to perform flow cytometry 
analysis. Fluorescent-labeled NPs were incubated with LN229 cells in 
medium with at final concentration corresponding to their IC50 at 72 h. 
After 1, 3, 6, 24, 48 and 72 h of incubation at 37 °C, removal of attached 
NPs was accomplished by washing the cells with PBS at pH 7.4 for 1 min. 
Cells were then detached by trypsinization. The samples were subsequently 
washed twice and for each sample, 10,000 cells were measured with a 
FACScalibur flow cytometer (Becton Dickinson) using the CellQuest 
software (Becton Dickinson). After 6h and 72h of incubation of LN229 
cells with fluorescently labeled NPs, the cells were fixed for 20 minutes 
with a 3% (w/v) paraformaldehyde (PFA) solution and permeabilized for 
10 minutes with 0.1% (w/v) Triton X-100 in phosphate-buffered saline 
(PBS) at room temperature. To prevent nonspecific interactions of 
antibodies, the cells were treated for 2 hr in 5% bovine albumin serum 
(BSA) in PBS, then the cells were incubated with a specific mouse 
monoclonal Ab raised against vimentin (1:1,000 in blocking solution, 3% 
(w/w) BSA in TBS-Tween 0.1%, Sigma) for 2 hours at 37 ° C.  After 
several washes the cells were incubated with a secondary IgG goat anti-
mouse antibody (Alexa Fluor 633, Life Technologies, Carlsbad, CA) 
diluted 1:1,000 in blocking solution for 1 h at room temperature. The slides 
were mounted on microscope slides by Mowiol. The analyses were 
performed with a Zeiss LSM 510 microscope equipped with a plan-
apochromat objective X 63 (NA 1.4) in oil immersion. The fluorescences 
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of the Alexa 488 and Alexa 633 were collected in multi-track mode using 
BP505-530 and LP650 as emission filters, respectively. 
Confocal Microscopy Analysis of Double Immunofluorescence 
LN229 cells were treated with free ZOL or the different NPs formulations 
at a concentration equal to their IC50 at 72h. The cells were fixed for 20 
minutes with a 3% PFA solution and permeabilized for 10 minutes with 
0.1% (v/v) Triton X-100 in PBS at room temperature. To prevent 
nonspecific interactions of antibodies, the cells were treated for 2 hr in 5% 
(w/v) BSA in PBS, then the cells were incubated with a specific mouse 
monoclonal Ab raised against Vimentin (1:1000 in blocking solution, 3% 
BSA in TBS-Tween 0.1%, mouse, Sigma) for 2 hours at 37 ° C. After 
several washes the cells were incubated with a secondary IgG goat anti-
mouse antibody (Alexa Fluor 633, Life Technologies, Carlsbad, CA) 
diluted 1:1,000 in blocking solution for 1 h at room temperature. 
Subsequently, the cells were washed with PBS and incubated with specific 
rabbit polyclonal Ab against either glial fibrillary acidic protein (GFAP) 
(Ab7260, Abcam, Cambridge, United Kingdom) or the oligodendrocyte 
lineage genes 2 (Olig2) (Ab77953, Abcam, Cambridge, United Kingdom) 
diluted 1:1,000 in blocking solution, at 4 °C o/n. After additional washes, 
the cells were incubated with both a secondary IgG goat anti-mouse 
antibody (Alexa Fluor 633, Life Technologies, Carlsbad, CA) and a goat 
polyclonal anti-rabbit antibody (Alexa 488, Life Technologies, Carlsbad, 
CA) diluted 1:1,000 in blocking solution for 1 hour at room temperature. 
The slides were mounted on microscope slides by DAPI. The analysis was 
performed with a Zeiss LSM 510 microscope equipped with a plan-
apochromat objective X 63 (NA 1.4) in oil immersion. The fluorescences 
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of the Alexa 488 and Alexa 633 were collected in multi-track mode using 
BP505-530 and LP650 as emission filters, respectively.  
Cell proliferation by MTT assay 
After trypsinization, all cell lines were plated in 100L of medium in 96-
well plates at a density of 2 x 10
3
 cells/well. One day later the cells were 
treated with free ZOL, Tf-PLCaPZ NPs, plain Tf-PLCaP NPs, PLCaPZ 
NPs and plain PLCaP NPs  at concentrations ranging of ZOL from 0,78 to 
120M. Cell proliferation was evaluated by MTT assay as previously 
described (Marra M. et al., 2009).  
Drug combination studies 
For the evaluation of the synergism between the different NP formulations 
or free ZOL and TMZ on the growth inhibition of GBM cells, the cells 
were seeded in 96-multiwell plates at the density of 2x10
3
 cells/well. After 
24 h of incubation at 37˚C the cells were treated with different 
concentrations of Tf-PLCaPZ NPs, PLCaPZ NPs, free ZOL, TMZ. 
Alternatively, cells were treated simultaneously with TMZ and NP 
formulations or sequentially with TMZ followed by NP formulations and 
conversely. The evaluation of synergism was performed using dedicated 
software, CalcuSyn (Biosoft, Ferguson, MO), which measures the 
interaction between the drugs by calculating the indexes of combination 
(CIs). CI values <1, 1 and> 1 indicate synergism, additivity and 
antagonism, respectively. Drug combination studies were based on 
concentration-effect curves generated as a plot of the fraction of unaffected 
(surviving) cells vs. drug concentration after 72 h of treatment. Assessment 
of synergy was performed analyzing drug interaction by the Calcusyn 
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computer program (Biosoft, Ferguson, MO). Furthermore, we analyzed the 
specific contribution of the different NPs, free ZOL and TMZ on the 
cytotoxic effect of the combinations by calculating the potentiation factor 
(PF), defined as the ratio of the IC50 of either NPs, free ZOL and TMZ 
alone to the IC50 of the different combinations; a higher PF indicates a 
greater cytotoxicity. 
In vivo: Therapeutic efficacy in a heterotopic and orthotopic model of 
GBM 
Cell line 
Human U373MG GBM cells were transfected with pcDNA3-luc 
(U373MG-LUC) as previously described (Nardinocchi L. et al., 2010) and 
were grown in RPMI medium in a humidified incubator containing 5% 
CO2 at 37°C. 
In vivo experiments 
CD-1 male nude (nu/nu) mice, 6–8 weeks old and weighing 22–24 g were 
purchased from Charles River Laboratories (Calco, Italy). The procedures 
involving mice and care were in compliance with Regina Elena National 
Cancer Institute animal care guidelines and with international directives 
(directive 2010/63/EU of the European parliament and of the council; 
Guide for the Care and Use of Laboratory Animals, United States National 
Research Council, 2011). For  heterotopic experiments, immunosuppressed 
mice were injected intramuscularly (i.m.) into the hind leg muscles of mice 
at 3x10
6
 U373MG-LUC GBM cells /mouse. After 6 days (when a tumor 
mass of about 300mg was evident) mice were randomized, divided in five 
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groups and treatment started. The following groups were evaluated: 
untreated; free ZOL; plain Tf-PLCaP NPs; ZOL-containing Tf-PLCaPZ 
NPs, and ZOL-containing PLCaPZ NPs without Tf. Mice were treated 
intravenously (i.v.) with  the different NP formulations or with 20 μg of 
free ZOL, for three times a week for 3 consecutive weeks. This scheduling 
of treatment was chosen based on previous published experiments (Marra 
M. et al., 2012). Tumor sizes were measured three times a week in two 
dimensions by a caliper and tumor weight was calculated using the 
following formula: a×b
2
/2, where a and b are the long and short diameter of 
the tumor, respectively. Antitumor efficacy of treatments was assessed by 
the following end-points: a) percent tumor weight inhibition (TWI%); b) 
tumor growth delay, evaluated as T - C , where T and C are the median 
times  for treated and control tumors, respectively, to achieve equivalent 
size; c) complete tumor regression, defined as tumor disappearance, as 
evaluated by palpability, lasting for at least 10 days during or after 
treatment period; d) increase of mice survival by euthanizing the animals, 
for ethical reasons, when the tumors reached 3 g in weight; e) stable 
disease,  defined as the maintenance for at least three weeks of the same 
tumor weight as the start of treatment; f) complete response, defined as the 
disappearance of tumor, for at least three weeks in the course of  treatment. 
Each experimental group included six mice and experiments were repeated 
at least twice. 
For orthotopic experiments, mice were anesthetized with a combination of 
tiletamine–zolazepam (Telazol, Virbac, Carros, France) and xylazine 
(xylazine/ Rompun BAYER) given intramuscularly at 2 mg/kg and injected 
intracranially with U373 MG-LUC cells at 2.5 x 10
5
 cells/mouse, through 
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the center-middle area of the frontal bone to a 2-mm depth, using a 0.1 mL 
glass microsyringe and a 27-gauge disposable needle. One hour prior to 
intracranial implantation, the mice were weighed and pre-medicated with 
an orally administration of 0.5 mg/ kg/d of Metacam (meloxicam) in saline 
to control for post-operative pain and inflammation. The medication was 
carried out until the end of the experiment. Animals were closely 
monitored by visual inspection and weighed daily from start of treatment 
and sacrificed when signs of tumor burden (especially weight loss >20% 
and severe neurological dysfunction) were evident. The time to this 
moment since GBM cells injection is considered as ‘survival time'. Mice 
were treated i.v., starting at day 8 after cells injection, with plain Tf-PLCaP 
NPs, Tf-PLCaPZ NPs and PLCaPZ NPs at 20 µg/mouse of ZOL for three 
time a week for 3 consecutive weeks. Experiments with ZOL free were not 
performed due to the well-known inability of this drug to cross the BBB. 
Each experimental group included eight mice and experiments were 
repeated twice. 
Bioluminescence imaging analysis 
Mice bearing intra brain U373MG-LUC tumors were imaged using the 
IVIS imaging system 200 series (Caliper Life Sciences, Hopkinton, MA, 
USA). Briefly, mice were anesthetized with a combination of tiletamine–
zolazepam (Telazol, Virbac, Carros, France) and xylazine (xylazine/ 
Rompun BAYER) given intramuscularly at 2 mg/kg. Then mice were 
injected intraperitoneally with 150 mg/kg D-luciferin (Caliper Life 
Sciences), and imaged in the supine position 10 min after luciferin 
injection.  Imaging was performed at baseline  before the start compound 
administration  and several times during the experiment. Data were 
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acquired and analyzed using the living image software version 3.0 (Caliper 
Life Sciences). 
Statistical analysis 
For comparison of several groups, one-way ANOVA for multiple groups, 
followed by Newmane-Keuls test if P < 0.05 was performed using the 
GraphPad Prism version 5.0 software (GraphPad Software, Inc, San 
Diego,CA). All numerical data are expressed as mean ± SD, n = 3 or more, 
from 3 different experiments. Any p values less than 0.05 was considered 
statistically significant. 
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Results 
Here, in order to improve the specificity and the delivery of ZOL in GBM 
cells, we upgraded the earlier developed PLCaPZ NPs with human Tf. The 
protocol to prepare the PLCaPZ NPs was modified in order to introduce Tf 
on the NP surface without a significant alteration of the size as well as of 
the self-assembling characteristics. After a preliminary formulative phase 
(data not shown), we selected the optimized preparation condition to 
prepare Tf-PLCaPZ NPs. Physical characteristics of Tf-PLCaPZ NPs, i.e. 
size, surface charge and ZOL loading efficiency, are shown in Table I. 
When Tf was added to PEGylated cationic liposomes, a dramatic decrease 
in the net positive charge of the liposomes was observed. No significant 
change in the particles mean diameter as well as in the size distribution of 
the NPs was observed after functionalization of the PLCaPZ NPs with Tf. 
In particular, Tf-PLCaPZ NPs had a mean diameter of about 147 nm with a 
very narrow size distribution (PI< 0.2). Furthermore, chromatographic 
analysis of non-complexed ZOL showed an actual loading of ~100 g of 
ZOL/mg lipids, corresponding to a complexation efficiency of about 100%, 
in both  PLCaPZ NPs and Tf-PLCaPZ NPs (data not showed).  
Formulations 
Diameter 
(nm) ± SD 
I.P. ± SD ζ ± SD 
PLCaPZ NPs 147.5 ± 7.1 0.152 ± 0.06 +17.5 ± 5.6 
PEGylated cationic liposomes 140.0 ± 15.0 0.149± 0.04 +47.37 ± 3.5 
Tf-PEGylated cationic liposomes complex 142.4± 21.1 0.152± 0.08 +7.5 ± 2.0 
Tf-PLCaPZ NPs 147.7 ± 15.0 0.169 ± 0.05 +11.3 ± 1.1 
Table I. Physical characteristics of the different NP formulations. 
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Then, in order to evaluate the hemolytic activity of those NPs in human 
blood, hemolysis assay was performed. Figure 1 shows the hemolytic 
activity of the developed NPs when added in presence of erythrocytes. 
Interestingly, in all the cases no significant hemolytic activity was observed 
after incubation of a dispersion containing erythrocytes with the NPs 
developed. It is worth to note that after incubation with the NPs 
functionalized with Tf an additional significant reduction of the hemolytic 
activity compared to not targeted PLCaPZ NPs (p<0.001) was observed.  
 
Figure 1.  Hemolytic activities of Tf-PLCaPZ NPs. Data represented the means and 
standard deviations of three independent experiments. P values (***<0.001) were 
obtained comparing Tf-PLCaPZ NPs to PLCaPZ NPs. 
Expression of Tf receptor in GBM cells and cytotoxicity studies 
We have evaluated the anti-proliferative effects of free ZOL and of the 
different NP formulations on the three GBM cell lines with MTT viability 
assay. The cells were treated for 72 h and then the viability was evaluated. 
We have identified the concentration of the drugs able to inhibit the 50% of 
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cell growth (IC50) (Table II). We observed that the encapsulation of ZOL 
into NPs increased the cytotoxic activity of ZOL by reducing the IC50. 
Free ZOL induced a 50% growth inhibition at a concentration of 22, 69.8 
and 46 M (IC50) in LN229, U87 MG and U373 MG, respectively, and 
this effect was enhanced when ZOL was encapsulated into NPs. In fact, 
PLCaPZ NPs showed an IC50 equal to 9 M in LN229, 18 M in U87 MG 
and 20 M in U-373 MG, that was significantly lower than that one 
induced by free drug (Table II). Tf-PLCaPZ NPs caused a significant 
decrease of the IC50 compared to free ZOL but not respect to PLCaPZ NPs 
(11 M for LN229, 37 M for U87 MG and 39M for U373 MG) (Table 
II). In all the cases, plain NPs did not induce a significant growth inhibition 
demonstrating a very low cytotoxicity. 
CELL 
LINES 
ZOL 
(IC50 µM) 
PLCaPZ NPs 
(IC50 µM) 
Plain PLCaP 
NPs (IC50 
µM) 
Tf-PLCaPZ NPs 
(IC50 µM) 
Plain Tf-PLCaPZ 
NPs (IC50 µM) 
LN-229 22 ± 0.01 9.0 ± 0.06 >>120 ± 0.01 11.0 ± 0.03 >>120 ± 0.03 
U-87 MG 69.8 ± 0.02 18.0 ± 0.01 >>120 ± 0.04 39.0 ± 0.04 >>120 ± 0.01 
U-373 MG 46.0 ± 0.04 20.0 ± 0.03 >>120± 0.03 37.0 ± 0.02 >>120 ± 0.07 
Table II. IC50 values of NP formulation 
Thereafter, we investigated the expression of Tf type 1 receptor (CD71) in 
GBM cells by Western Blot. LN229, U87 MG and U373 MG cells were 
harvested after 72h of treatment with ZOL at a concentration equal to its 
IC50 at 72 h for each cell line. We used prostate cancer cells PC-3 as a 
positive control. The receptor was expressed in all GBM cell lines at 
baseline and treatment with ZOL did not significantly modulate TfR 
expression. As expected, PC-3 expressed the receptor at high levels. The 
expression of -tubulin was assessed as loading control (Figure 2).  
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Figure 2. Western Blot analysis of the TfR levels in GBM cells. 
On the bases of these results, we evaluated the basal expression of the TfR 
both on the cell membrane and at the intracellular level on all GBM cell 
lines by FACS analysis. The receptor was expressed at higher levels in 
LN229 both on the membrane and at the intracellular level while the U373 
MG and U87 MG cells expressed the receptor at lower levels both on the 
membrane and at intracellular level (Figure 3). Interestingly, LN229 cell 
line was also the most responsive to the inhibitory effects of Tf-PLCaPZ 
NPs. 
 
Figure 3. Basal expression of the TfR both on the cell membrane and at the intracellular 
level on all GBM cell lines by FACS analysis. 
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Tf-PLCaPZ NPs uptake and intracellular distribution 
To investigate the NPs uptake and the intracellular distribution, 
fluorescently labeled NPs were used on LN229 cells. The fluorescence 
associated to the cells was evaluated by both FACS and confocal laser 
scanning microscopy (CLSM). FACS analysis of LN229 cells after 1, 3, 6, 
24, 48, and 72h hours of incubation with fluorescently labeled NPs (Figure 
4) was performed. In particular, after 6h of incubation with PLCaPZ NPs or 
Tf-PLCaPZ NPs, FACS analysis revealed the highest increase in the % of 
mean fluorescence intensity (MFI) associated to the cells, thus showing 
NPs uptake as compared with the untreated control (Figure 4 A). MFI of 
control was considered as 100%; after 6h of cell incubation Tf-PLCaPZ 
NPs induced a significantly higher MFI increase (450%) as compared with 
PLCaPZ NPs (370%) (Figure 4 B).  In both cases, MFIs decreased in a 
time-dependent manner after 24h.  
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Figure 4. A. FACS analysis of LN229 cells after 1, 3, 6, 24, 48 and 72 h of incubation 
at 37 °C with Bodipy-labeled NPs. The experiments were performed at least three 
different times and the results were always similar. B. Mean fluorescence intensity 
(MFI), expressed as % of unexposed cells, of cells exposed to the different NPs 
formulations. 
The uptake and intracellular distribution of fluorescently labeled NPs after 
6 and 72h of incubation was studied also by confocal microscopy. After 6h, 
CLSM results showed a widespread and intense fluorescence, with 
perinuclear green spots into the cytoplasm, for cells incubated with Tf-
PLCaPZ NPs (Figure 5). Cells treated with PLCaPZ NPs, compared to Tf-
PLCaPZ NPs, evidenced a significant lower fluorescence intensity. A green 
fluorescence was observed also in the cells incubated with plain NPs and in 
particular, plain Tf-PLCaP NPs showed the higher fluorescence intensity 
(Figure 5). After 72h, the fluorescence intensity decreased in all the cases 
(Figure 5). Therefore, the intracellular uptake of NPs could contribute to 
increasing the amount of ZOL that reaches its cytoplasmic targets. 
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Figure 5. Confocal microscopy images of LN229 after 6 and 72 h of incubation at 37 
°C with fluorescently-labeled NPs. Representative images of CTR (A), Plain PLCaP 
NPs (B), PLCaPZ NPs (C), ZOL (D), Plain Tf-PLCaP NPs (E), Tf-PLCaPZ NPs (F). 
The cells were visualized with a confocal microscope at magnification 100x. 
Effects of Tf-PLCaPZ NPs on the differentiation of GBM cells 
After 48h of treatment with Tf-PLCaPZ NPs at a concentration 
corresponding to its IC50, we observed that LN229 cells changed their 
shape. In details, Tf-PLCaPZ NPs induced a significant cell elongation that 
was higher than that one induced by free ZOL and PLCaPZ NPs.  As cell 
elongation can be correlated with cell differentiation, we have studied two 
differentiation markers, Olig2 and GFAP that were assessed at CLSM. In 
details, Olig2 showed a well distributed higher fluorescence for cells 
incubated with Tf-PLCaPZ NPs as compared to free ZOL or PLCaPZ NPs 
(Figure 6). Cells treated with Tf-PLCaPZ NPs evidenced widespread lower 
fluorescence intensity for GFAP as compared to Olig2 expression (Figure 
6). These data suggest that the treatment of LN229 cells with ZOL induced 
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a differentiation towards an oligodendrocyte phenotype and that this effect 
was strongly enhanced by the delivery of the agent by Tf-PLCaPZ NPs. 
 
Figure 6. Effects of the NPs on the differentiation of LN229 cells. Confocal 
microscopy images of LN229 after 48 h of incubation at 37 °C with PBS (A), ZOL (B), 
PLCaPZ NPs (C) or Tf-PLCaPZ NPs (D) at a concentration equal to their IC50s. The 
cells were incubated with anti-vimentin antibody (red) (Santa Cruz Biotechnology, Inc.) 
and either anti-Olig2 antibody (green, right panels) (Abcam) or anti-GFAP antibody 
(green, left panels) (Abcam) for 1 hour. The slides were mounted with DAPI. The cells 
were visualized with a fluorescent microscope at   magnification (100x). Arrows show 
examples of fluorescence due to Olig2 or GFAP specific staining. 
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Anti-proliferative effects of the sequential administration of Tf-PLCaPZ 
NPs and TMZ on GBM cells 
A conventionally used cytostatic agent for the treatment of GBM in 
combination with radiation therapy or alone after surgery and radiotherapy 
is TMZ. On these bases, we evaluated the growth inhibition induced by 
TMZ on the three GBM cell lines. After 72h the IC50s of TMZ were 176 
M, 95 M and 110 M for LN-229, U87 MG, U373 MG, respectively 
(Table III).  
CELL LINES TMZ M IC50 
LN-229 176±0.02 
U-87 MG 95±0.03 
U-373 MG 110±0.02 
Table III. IC50 values of TMZ 
These data were used to assess the effects of TMZ in combination with the 
different NP formulations and in different sequences of cell exposure. In 
details, we added to the cells TMZ for 72 h and NPs for 48h or vice versa 
or we simultaneously treated the cells with TMZ and NP formulations for 
72h. Analyzing the results, when free ZOL or the different NPs were 
simultaneously added to the cells with TMZ, a significant reduction of the 
anti-proliferative activity, compared to the administration of the single 
agents, was observed. A slight synergistic effect was observed only in U-
373 MG cells, after treatment with the combinations PLCaPZ NPs/TMZ 
and Tf-PLCaPZ NPs/TMZ. On the contrary, better results were obtained 
when TMZ was added to the cells before both free ZOL, PLCaPZ NPs or 
Tf-PLCaPZ NPs. In this case, a synergistic effect was observed in all the 
three GBM cell lines (Figure 7C). Interestingly, TMZ followed by Tf-
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PLCaPZ NPs was strongly synergistic on LN229 cells (IC50= 0.42) (Figure 
7C). Similarly, TMZ followed by free ZOL was highly synergistic on the 
U87 MG cells (IC50 = 0.43). The reverse sequences (ZOL, PLCaPZ NPs or 
Tf-PLCaPZ NPs followed by TMZ) were in almost all the cases 
antagonistic or additive on the inhibition of the proliferation of all the 
GBM cell lines (Figure 7B).  Only the sequences Tf-PLCaPZ NPs/TMZ 
and PLCaPZ NPs/TMZ were strongly synergistic on the growth inhibition 
of LN229 and U373 MG cells, respectively, with an IC50 =0.30 and IC50 
= 0.43, respectively (Figure 7B).  
 
Figure 7. Effects of the TMZ/NPs sequence on the cell growth. A. Simultaneous 
treatment of GBM cell with TMZ and NP formulations. B. Sequential treatment of ZOL 
or NPs formulations followed by TMZ. C. Sequential treatment of TMZ followed by 
ZOL or NPs formulations.   
Subsequently, we calculated the potentiation factor (PF) for treatments that 
showed synergism. The PF is the ratio between the IC50 of the drug used 
alone and the IC50 of the drug used in the combination: if PF is greater 
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than 1, it means that the drug in combination determines its anti-
proliferative effect at a lower concentration compared to the drug alone. In 
our experimental conditions, PF was much more higher when TMZ was 
added to the cells before the other drugs  (ZOL, PLCaPZ NPs, Tf-PLCaPZ 
NPs) (Table IV). These data suggest that Tf-PLCaPZ NPs strongly 
potentiated the anticancer effects of TMZ when they are added to the cells 
after the cytotoxic drug. 
Table IV. PFs of the synergistic pharmacological combinations. 
Antitumor efficacy of Tf-PLCaPZ NPs  in heterotopic model of GBM 
In order to evaluate the in vivo effects of NPs formulations, we inoculated 
i.m. 3 x 10
6
 U373MG-LUC cells into immunosuppressed mice. U-373MG-
LUC cells allow the in vivo monitoring of tumor growth by imaging 
performed as a function of the bioluminescent signal generated by the 
catalysis of D-luciferin, injected in the animal at the time of imaging.  After 
6 days, when the tumor mass became palpable and visible by luminescence 
analysis, the mice were divided into five groups: untreated mice, mice 
treated with free ZOL, with plain NPs functionalized with Tf, with Tf-
PLCaPZ NPs and with plain and PLCaPZ NPs.  
 
 
Cell lines                           TMZ → ZOL         TMZ → PLCaPZ NPs     TMZ →Tf-PLCaPZ NPs 
LN - 229 
 
 
 
U - 373 MG  
U - 87 MG 
PF 
TMZ = 3.7              PF TMZ = 4.3                  PF TMZ = 12.6 
 
PF
ZOL = 4.0               PFPLCaPZ NPs = 1.4              PFTf-PLCaPZ NPs= 10.0 
PF 
TMZ = 7.3              PF TMZ = 1.5                  PF TMZ = 1.4 
 
PF
ZOL = 1.8               PFPLCaPZ NPs= 1.8               PFTf-PLCaPZ NPs = 10.0 
PF 
TMZ = 1.3              PF TMZ = 2.0                  PF TMZ = 3.0 
 
PF
ZOL = 1.9               PFPLCaPZ NPs = 3.2              PFTf-PLCaPZ NPs= 2.2 
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In figure 8 are reported the bioluminescence analysis of U373MG-LUC 
tumors treated with the different formulations. It is evident that Tf-PLCaPZ 
NPs exhibited the highest antitumor efficacy. In fact, this treatment 
produced, at nadir of the effect,  a significant (P= 0.009 vs untreated) tumor 
weight inhibition of 41%, while the non-functionalized PLCaPZ NPs 
reduced of 31% the growth of tumors (P= 0.02)  and  free ZOL resulted in a 
not particularly marked tumor growth inhibition (TWI 20%).   The good 
therapeutic efficacy of  Tf-PLCaPZ NPs is also demonstrated by the 
significant (P= 0.03) delay of tumor growth (10 days) and by the increase 
of life survival of mice (23%). Interestingly, this treatment produced a 
complete tumor response in 1 out of six mice treated, while PLCaPZ NPs 
produce a stabilization of disease in 1 out of six mice treated. Finally, it is 
interesting to note that, all treatments were well tolerated by the animals, as 
there were no toxic deaths or weight loss in animals (data not showed). 
 
Figure 8. Bioluminescence analysis of a heterotopic model of GBM. 
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Antitumor efficacy of Tf-PLCaPZ NPs  in an orthotopic model of GBM 
Based on the promising results obtained in vitro and in vivo, we 
subsequently evaluated the therapeutic efficacy of these formulations on 
orthotopic  mice bearing GBM tumors. We inoculated intrabrain 2.5 x 10
5
 
U-373MG-LUC cells into immuno-compromised mice. This tumor model 
closely recapitulated histological phenotypes consistent with those of 
human GBM. After 8 days, when the tumor mass became visible by 
bioluminescence analysis, the mice were divided into four groups: 
untreated mice, mice treated with plain NPs functionalized with Tf, mice 
treated with Tf-PLCaPZ NPs and mice treated with PLCaPZ NPs. As 
reported in Figure 9, NPs containing ZOL formulations were effective in 
limiting the growth of GBM and in particular, Tf-PLCaPZ NPs reduced the 
tumor mass and elicited the healing of some treated animals. In fact, while  
all untreated or mice treated with plain NPs showed a progression of the 
disease, the treatment with NPs containing ZOL produced the stabilization 
of the disease in 2 out of eight mice treated. Interestingly, Tf-PLCaPZ NPs 
elicited a more strong antitumor effect determining the stabilization of the 
tumor mass in 2 out of eight mice and a decrease followed by a complete 
disappearance of the  tumor in 1 out of eight mice. (Figure 9). At this time, 
six months or more after the end of treatment, mice with complete tumor 
regression are still alive and in good conditions and bioluminescence 
analysis did not show the presence of tumor cells in the brain of mice. The 
higher efficacy of Tf-PLCaPZ NPs than PLCaPZ NPs was demonstrated by 
the increase of overall survival of mice (23 vs 13%, respectively), while 
plain Tf-PLCaP NPs treatment was uneffective.  
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Figure 9. Anti-cancer activity of Tf-PLCaPZ NPs in an orthotopic model of GBM. 
Overall, our results clearly demonstrate the therapeutic efficacy of PLCaPZ 
NPs functionalized with Tf against experimental models of human GBM 
even on orthotopic tumors that closely mimics the clinical setting. 
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Discussion  
In the present study, we have proposed a new strategy to inhibit GBM 
cells growth. In a previous work, we demonstrated that self-assembled NPs 
could be used to successfully deliver ZOL in different cell lines, with a 
strong potentiation of its anti-cancer effect (Salzano G. et al., 2011). These 
effects were then confirmed in vivo in an experimental model of prostate 
cancer (Marra M. et al., 2012). On the basis of these interesting results, it 
should be attractive to use this technology for the delivery of ZOL also in 
tumors as GBM that, at the moment, are very difficult to treat, also in vitro. 
To this aim, earlier developed self-assembled NPs have been potentiated in 
order to target TfR, which is overexpressed in different cancer cells, such 
as GBM. Tf has been successfully used for active targeting of cancer cells 
and Tf-modified NPs are at the moment in clinical trials (Daniels T.R. et 
al., 2012). The biological significance of Tf peptide and its receptor has 
been thoroughly characterized and its relevance when applied to targeting 
strategies has been widely reported (Daniels T.R. et al., 2012). It has been 
found a direct correlation between increased expression of Tf receptor and 
the levels of malignancy in a wide range of tumors, including glioma 
(Recht L. et al., 1990). In addition, Tf is the major peptide involved in the 
transportation of iron from the blood into the brain (Burdo J.R. et al., 
2003). All this knowledge about the physiological function and expression 
of Tf and its role in drug delivery provides rationale for the development of 
Tf-targeted NPs to improve the delivery of a promising anti-cancer agents, 
such as ZOL, in GBM cells. 
The first task of this work consisted in modifying with Tf the surface of 
the self-assembling NPs, previously developed by our group, sparing their 
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self-assembling characteristics. This propriety should allow the formation 
of these NPs easily before use, thus avoiding stability and scale-up.  
Therefore, the first step of the work was to change the preparation 
protocol to conjugate Tf on the surface of the NPs without altering their 
physical characteristics. The inclusion of Tf in the protocol and in 
particular the Tf mixing with PEGylated cationic liposomes before 
complexation with CaPZ, did not result in a significant change in terms of 
mean diameter, P.I. and ZOL encapsulation efficiency (Table I). Tf 
complexation with PEGylated cationic liposomes resulted in a strong 
decrease of the ζ, thus indicating efficient charge shielding, reasonably due 
to the presence of Tf on the vesicle surface (Table I). Then, in order to 
determine if the surface modification could influence the hemolytic 
potential of the Tf-modified NPs, the erythrocytes activity was evaluated in 
human blood samples using a previously reported method slightly modified 
(Chen C. et al., 2008).  The instability of therapeutic NPs in the blood is 
considered to be one of the serious limitations in their clinical use. In 
particular, carrier based on cationic lipids often present hemolytic activity 
at certain concentrations (Hägerstrand H. et al., 2001). Here, we have 
investigated if the presence of cationic lipids in the developed NPs can led 
to an erythrocyte toxicity. Our results revealed that, at the concentration 
used in the in vitro studies, non-targeted PLCaPZ NPs showed a limited 
hemolytic activity (of ~ 5%). The presence of PEG chain in the NPs 
formulation could contribute to the low hemolytic activity of these NPs, 
probably due to a shielding effect on the surface positive charge (Kainthan 
R.K. et al., 2006). Interestingly, Tf-PLCaPZ NPs showed almost no 
hemolytic activity, since, according to ASTM F 756–08 a hemolytic 
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activity less than 2% is generally regarded to a non-toxic effect level 
(ASTM F-756, 2009) (Figure 1). Since Tf possesses a net negative charge, 
its introduction on the surface of the NPs reduced significantly the rate of 
hemolysis compared to no-targeted PLCaPZ NPs (~1% versus ~5%, 
respectively). Therefore, the significant low rate of hemolysis (p<0.001) 
observed by using Tf-PLCaPZ NPs can be correlated to the ability of Tf to 
shield more efficiently the positive charge of the NPs. In addition, the use 
of a physiological molecule, such as Tf, could further contribute to a 
biocompatibility of these NPs.  
Consequently, we evaluated the effect of NPs functionalization in GBM 
cell lines. First of all, we evaluated if the GBM cells expressed significant 
levels of TfR by Western blot analysis. Our results showed that all the three 
GBM cell lines expressed TfR, with the highest levels in LN229 cells 
(Figure 2). Interestingly, in LN229 cells, we observed a significant uptake 
of Tf-PLCaPZ NPs, visualized by confocal microscopy and FACS analysis, 
suggesting a correlation between the higher levels of Tf in this cell line and 
the cell internalization of Tf-PLCaPZ NPs. Moreover, if compared to no 
targeted PLCaPZ NPs, the cell uptake of Tf-PLCaPZ NP was significantly 
enhanced (Figure 3).  
Moreover, Tf-PLCaPZ NPs were able to induce morphological changes 
in LN229 cells. In particular, Tf-PLCaPZ NPs elicited a significant cell 
elongation that was much higher than the one induced by free ZOL or by 
PLCaPZ NPs (Figure 4). To evaluate the biological mechanisms on the 
basis of the morphological change in LN229 cells, we analyzed in the 
treated cells, the levels of two differentiation markers, Olig2 and GFAP. 
GBM is an anaplastic brain tumor characterized by poorly differentiated 
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neoplastic cells (Sampetrean O. et al., 2013) and it is highly refractory to 
conventional modalities of treatment. It has been found a direct correlation 
between the levels of Olig2 and GFAP and the response to 
chemotherapeutic agents. In particular, glial tumors characterized by high 
levels of Olig2 and low levels of GFAP (Olig2
+
/GFAP
-
), a condition 
usually found in oligodendroglioma, are characterized by better prognosis, 
higher chemosensitivity and better survival (Mokhtari K. et al., 2005). 
Interestingly, we found that, Tf-PLCaPZ NPs treated LN229 cells 
expressed higher levels of Olig2 rather than GFAP as compared with free 
ZOL or PLCaPZ NPs (Figure 4). These results suggest that the treatment 
with Tf-PLCaPZ NPs could induce an oligodendrocytic differentiation of 
the LN229 GBM cells. 
In a second phase of the study, we investigated the possibility to 
combine Tf-PLCaPZ NPs with a chemotherapeutic agent, TMZ. TMZ is 
currently the first line of choice for the treatment of GBM, together with 
radiotherapy. However, its effectiveness is often limited and it seems to act 
above all as radiosensitizers in the classical Stupp schedule that represents 
the gold standard in the treatment of GBM in the first line of treatment 
while fotemustine is used in the second line (Addeo R. et al., 2009). 
In our preliminary study, we found that the treatment of GBM cells with 
free TMZ was characterized by an in vitro refractoriness to TMZ (Table II). 
On the contrary, the treatment with free ZOL or ZOL incorporated in either 
PLCaPZ NPs or Tf-PLCaPZ NPs induced a more potent effect on the 
growth inhibition of GBM cells if compared to TMZ (Table III). In order to 
investigate if the treatment with NP formulations containing ZOL could 
sensitize GBM cells to TMZ, synergistic studies were performed. 
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Previously, it has been reported a synergistic effect of ZOL in combination 
with conventional cytotoxic drugs (doxorubicin or docetaxel) in particular 
when these were added to either breast cancer cells or prostate cancer cells 
before ZOL (Facchini G. et al., 2010).  Here, we have studied the 
synergistic effect of ZOL and TMZ in different sequences of 
administration. In all the GBM cells, we found a synergistic effect when 
ZOL was added after TMZ (Figure 6). On the other hand, the concomitant 
treatment of ZOL and TMZ did not result in a substantial synergism (data 
not shown). It is worth to note that in all the cases, the treatment of GBM 
cells with ZOL-containing NPs potentiated the synergistic effect (Table 
IV). Tf-PLCaPZ NPs appeared to be more active when administered in 
combination with TMZ on LN-229 cells that express higher levels of TfR. 
These results suggest that the high expression of TfR may improve the 
binding and the subsequent internalization of Tf-functionalized NPs and 
consequently potentiate the antitumor activity of ZOL. It is also interesting 
to note that, only when using Tf-PLCaPZ NPs, even in the reverse order of 
administration of TMZ, is possible to find a strong synergism on LN-229 
cells (Figure 6).  
Finally, we investigated the ability of the Tf-PLCaPZ NPs to overcome 
the BBB and their consequent efficacy on the inhibition of the tumor 
growth in an orthotopic  model of GBM.  Interestingly, we found a marked 
therapeutic efficacy of Tf-PLCaPZ NPs since, in mice treated with this 
formulation, a stabilization of the disease and a complete response with 
regression of tumor was observed (Figure 9).  
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Conclusions 
We have proposed a new strategy to efficiently use ZOL for the 
treatment of GBM.  The developed Tf-PLCaPZ NPs allows for both easy 
upgrade of the NPs with specific ligands and high ZOL incorporation.  The 
Tf-targeted NPs showed high colloidal stability and small particle sizes. 
The Tf-PLCaPZ NPs were able to efficiently accumulate into LN229 GBM 
cells and to consequently inhibit their growth. In addition, the treatment 
with Tf-PLCaPZ NPs mediated a potent sensitization of GBM cells to non-
effective doses of TMZ. Moreover, the functionalization of NPs with Tf 
was able to increase the anti-tumor activity of ZOL in vivo, in a GBM 
orthotropic model. The successful pharmacological effect on mice, which 
resulted in a stabilization of the tumor in all the treated animals and in a 
complete regression of the tumor in a significant percentage of treated 
animals, opens a new prospective for the future clinical use of ZOL in 
treatment of brain tumors. 
 
 
 
 
 
 
 
 
 
 
Chapter 2 
 
 
 
 
“Multifunctional polymeric micelles for the co-delivery of an 
anti-survivin siRNA and paclitaxel for the reversal of drug 
resistance in ovarian cancer”
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Summary 
     Small interfering RNA (siRNA) are double stranded RNA-based 
oligonucleotide with the possibility to specifically inhibit a target protein. 
This potential represent a powerful therapeutic opportunity to treat different 
form of cancer, among them also form of multiresistant cancer, such as 
ovarian cancer. This is the second most common gynecological malignancy 
worldwide. Its current therapy is based on cytoreductive surgery followed 
by platinum and taxane-based combination chemotherapy. However, after 
an unpredictable time of response to therapy, a high percentage of patients 
undergo to a resistant phase. The discovery that survivin, a small anti-
apoptotic protein, is involved in chemoresistance, opens a new scenario to 
overcome multidrug resistance (MDR) in cancer, since siRNA could be 
used to inhibit the expression of survivin in cancer cells. Interestingly, it 
has been found that the down-regulation of survivin by siRNA sensitizes 
cancer cells to chemotherapeutic agents, such as paclitaxel (PXL).  
However, the clinical use of siRNA is still hampered by an unfavorable 
pharmacokinetic profile. To address this problem, we developed a novel 
system to stabilize and deliver siRNA into cancer cells. Namely, we 
reversibly modified an anti-survivin siRNA with a phosphothioethanol 
(PE) portion via a reducible disulfide bond and incorporated the resulting 
siRNA-S-S-PE conjugate into nanosized polyethyelene glycol2000-
phosphatidyl ethanolamine (PEG2000-PE)-based polymeric micelles (PM), 
obtaining the so-called survivin siRNA PM.  The activity of these 
nanopreparations was evaluated in different cancer cell lines by survivin 
protein down-regulation, tumor cell growth inhibition, and 
chemosensitization of the treated tumor cells to paclitaxel (PXL). In all the 
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survivin siRNA PM treated cells, we found a significant decrease of cell 
viability and down-regulation of survivin protein levels. In addition, the 
down-regulation of survivin by treating cells with survivin siRNA PM, 
elicited a significant sensitization of the cells to PXL, in both sensitive and 
resistant cancer cell lines. In a second phase of the project, we investigated 
the possibility to co-incorporate anti-survivin siRNA and PXL in the same 
PM for combined therapy. To this purpose, we developed PMs co-loaded 
with PXL and anti-survivin siRNA, the so-called survivin siRNA/PXL PM. 
These multifunctional PMs were prepared by a method very easy to 
reproduce. The activity of the combination was evaluated in vitro on a 
PXL-resistant ovarian cancer cell lines, SKOV3-tr. We demonstrated 
successful co-delivery of PXL and survivin siRNA in the same PMs 
leading to superior therapeutic activity compared to their sequential 
administration. Finally, to confirm the encouraging in vitro results, the 
antitumor efficiency of the developed multifunctional PM was evaluated in 
an animal model of SKOV3-tr. Changes in survivin expression, therapeutic 
efficacy and biological effects of the multifunctional PM, were 
investigated. Interestingly, the results on xenografed SKOV3-tr mice, 
revealed a significant down-regulation of survivin expression in tumor 
tissues together with a potent anticancer activity by using survivin 
siRNA/PXL PM. In the same model, tumor growth was unaffected when 
using free PXL.  These results demonstrated that survivin siRNA/PXL-co-
loaded PM elicited a significant inhibition of the tumor growth of a human 
xenograft model of SKOV3-tr in mice and encourage the future pre-clinical 
development of survivin siRNA/PXL PM for the treatment of this and other 
chemo-resistant  tumors. 
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Introduction 
Survivin, the smallest member of the inhibitors of apoptosis (IAP) 
family, has gained much attention in recent years as a promising new target 
in cancer therapy due to its differential expression in tumors compared to 
normal tissues (Ambrosini G. et al., 1997). Survivin plays an important role 
in the negative regulation of apoptosis as well as in cell division (Altieri 
D.C., 2003;  Yang D. et al., 2004). Moreover, survivin expression in 
malignant tissues has been correlated with drug resistance (Lu J. et al., 
2009). Accordingly, inhibition of survivin has been of clear interest for 
cancer therapy. In the last years, many researchers have proposed various 
ways to counteract survivin activity in cancer cells with the aim to inhibit 
the tumor growth potential and to sensitize the tumor cells to 
chemotherapeutic agents. RNA interference (RNAi), a cellular post-
transcriptional gene silencing mechanism, offers an attractive and powerful 
approach to efficiently inhibit survivin expression in cancer cells (Fire A. et 
al., 1998). RNAi can be induced by double-stranded small interfering RNA 
(siRNA) consisting of 21-25 nucleotides that degrades a target mRNA in a 
highly sequence specific manner (McManus M.T. et al., 2002; Hannon G.J. 
et al., 2004; Caplen N.J. et al., 2001).  Carvalho A. et al. (2003) were the 
first to use siRNA to suppress survivin levels in HeLa cells, showing a 
specific depletion of survivin for at least 60 h after the transfection with a 
specific siRNA. Seth et al. have demonstrated the in vivo silencing of 
survivin and a significant dose-dependent decrease of tumor volumes after 
intravesical instillation of liposomes containing survivin siRNA in an 
animal model of bladder cancer (Seth S. et al., 2011).  
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   Despite all the potential of siRNA in cancer treatment, selective 
inhibition of an over-expressed gene via RNAi requires an effective 
delivery strategy that ameliorates the significant issues associated with its 
pharmacokinetic profile. In particular, the poor stability in biological fluids 
and the low cellular uptake impaired siRNA direct use in clinical trials. In 
the literature, a wide number of non-viral delivery carriers, including 
liposomes (Zimmerman T.S. et al., 2006;  Landen C.N. et al., 2005), lipids 
(Santel A. et al., 2006; Yano J. et al., 2004), polymers (Kim S.H. et al., 
2006; Urban-Klein B. et al., 2005), peptides (Mok H. et al., 2008), virus-
based vectors (Grimm D. et al., 2006), and pressurized hydrodynamic 
injection (Song E. et al., 2003), have been suggested for improved 
intracellular delivery of siRNA. However, only few have demonstrated 
clinical applicability due to toxicity and poor stability in biological fluids. 
Recently, it has been reported that direct conjugation of small drug 
molecules, aptamers, lipids, peptides, proteins, or polymers to siRNA could 
improve in vivo pharmacokinetic behavior of siRNA, prolong its half-life, 
and increase its delivery efficiency (Nishina K. et al., 2008;  Chu T.C. et 
al., 2006;  Kim S.H. et al., 2006; Lorenz C. et al.,2004; Moschos S.A. et 
al.,2007; Muratovska A. et al., 2004; Soutschek J. et al., 2004). However, 
chemical modification of siRNA can affect its activity and specificity, and 
in such conjugates, siRNA still remains open for degradation by nucleases. 
Therefore, the transition of siRNA-based approach to the clinical setting 
requires the development of a suitable delivery system which thoroughly 
protects siRNA from degradation in vivo and at the same time is capable of 
releasing free siRNA when inside cell. With this in mind, the research 
group led by Dr. Torchilin V.P. have designed a novel “reversible” siRNA 
49 
 
by attaching siRNA to the phospholipid (PE) via a disulfide linkage, the so-
called siRNA-S-S-PE conjugate (Figure 1), (Musacchio T. et al., 2010). 
 
Figure 1. Schematic representation of siRNA-S-S-PE synthesis. 
 This strategy is based on the high concentration of reductases in the 
tumor microenvironment over normal tissues (Balendiran G.K. et al., 2004) 
as well as glutathione inside cancer cells (Estrela J.M. et al., 2006). In 
particular, when inside the cell, the S-S linkage in a such conjugate will be 
reduced by the high intracellular glutathione (GSH) and liberate the native 
siRNA into the cytoplasm. Then, to further protect siRNA-S-S-PE from the 
nucleolytic degradation on its route to the target, the siRNA-S-S-PE 
conjugate was incorporated via its hydrophobic PE moiety, into PEG2000-
PE-based stable polymeric micelles known to have high stability, 
prolonged circulation, and accumulation in the areas with an abnormal 
vascularization, i.e. tumors, via the enhanced permeability and retention 
(EPR) effect in pathological areas in vivo (Sawant R.R. et al., 2010). Such 
micelles can be also modified to target specific cells (Sawant R.R. et al., 
2010). Therefore, the chemical conjugation of  siRNA and its incorporation 
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as conjugate into PM offers the dual advantage of protecting the siRNA 
from degradation in vitro and at the same time, the cleavable disulfide 
bonds linked to the siRNA, allows to liberate it as free when inside the cell 
for target-specific gene silencing (Musacchio T. et al., 2010).  
Here, we formulated nanosized PEG2000-PE  PM for anti-survivin 
siRNA delivery (Salzano G. et al., 2014). In particular, we developed easy-
to-obtain PM through self-assembly of amphiphilic block of PEG2000-PE 
polymers in an aqueous environment containing preformed survivin 
siRNA-S-S-PE conjugate. The technological parameters have been 
optimized in order to obtain PM that can be prepared immediately before  
use overcoming problems of stability during the storage of many colloidal 
systems, such as liposomes (Torchilin V.P. et al., 2003). In fact, the 
developed PM can be prepared offhand by mixing at room temperature pre-
formed polymeric film of PEG2000-PE with a dispersion containing anti-
survivin siRNA-S-S-PE conjugate. After few minutes of simple mixing the 
formulation is ready to be injected. Then, the size characteristics of the 
PMs, the incorporation efficiency of survivin siRNA,  the stability of the 
siRNA against nuclease and the capability of the disulfide linkage to be 
cleavage in reducing conditions, were investigated.  In a second step, the 
activity of the developed survivin siRNA PMs was evaluated in vitro by 
measuring the survivin protein levels and cytotoxic effect in different 
cancer cell lines. In vitro cytotoxicity and survivin protein levels assays 
revealed the ability of survivin siRNA PMs to efficiently inhibit the cell 
growth and to down-regulate the survivin in different cancer cell lines.  
In a second phase of the project,  we investigated the potential of 
combining anti-survivin siRNA and a chemotherapeutic agents, PXL, 
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within one multifunctional nano-assembly; the aim was to achieve a 
synergistic effect of the two agents for the treatment of aggressive ovarian 
cancer. PXL exhibits its anticancer activity by promoting tubulin 
polymerization and stabilizing microtubules, which results in mitotic G2/M 
arrest and apoptosis (Gallagher Jr. B.M. et al., 2007). The clinical 
effectiveness of PXL, an agent widely used in clinic for the treatment of 
several tumors, such as ovarian cancer, is often hampered by acquired drug 
resistance (Singla A.K., et al., 2002). Since sensitization to PXL by 
survivin down-regulation has been reported (Shen J. et al., 2012; Shen J. et 
al., 2013; Hu Q. et al., 2012), we evaluated co-treatments with PXL and 
anti-survivin siRNA. The over-expression of survivin has been associated 
with poor prognosis and aggressiveness  of the tumors (Salz W. et al., 
2005). In advanced ovarian carcinomas, it has been found that forced 
expression of survivin are directly correlated with a clinical resistance to 
taxane chemotherapy (Zaffaroni N. et al., 2002).  
To this purpose, we upgraded the developed PM by co-encapsulating 
anti-survivin siRNA and PXL in the same PM. The so-called survivin 
siRNA/PXL PM showed optimal technological characteristics, highlighting 
the ability of the PM to efficiently co-encapsulate chemotherapeutic agents 
and siRNA for multifunctional therapy. Then, we investigated the 
therapeutic potential of the developed multifunctional PM, namely survivin 
siRNA/PXL PM, especially concerning the anti-cancer activity in a 
xenografts model of PXL-resistant ovarian carcinoma, SKOV3-tr. 
Moreover, the gene silencing and the biochemical effects of the 
formulation were studied on tumors collected from animals after the 
treatment.  
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Materials and Methods 
Materials 
Unless otherwise stated all chemicals were from Sigma-Aldrich (Saint 
Louis, MO, USA). Survivin siRNA with the following sense sequence 5’-
GCAUUCGUCCGGUUGCGCUdTdT-3’ and a scrambled siRNA with the 
following sense sequence 5’-AUGAACUUCAGGGUCAGCUdTdT-3’ 
have been used. Both siRNAs modified at the 3′-end of the sense strand 
with N-succinimidyl 3-(2-pyridyldithio)propionate (SPDP) group were 
purchased from Thermo Scientific Dharmacon (Pittsburgh PA, USA).  The 
paclitaxel (PXL) was purchased from LC Laboratories (Woburn MA, 
United States). The Paclitaxel Oregon green (P22310) was from Invitrogen, 
CA. The 1,2-dipalmitoyl-sn-glycero-3-phosphothioethanol (PE-SH, MW 
731) and 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-
[methoxy(poly(ethyleneglycol))-2000](PEG2000-PE) were from Avanti 
Polar Lipids (Alabaster, AL). The d-Salt dextran desalting column was 
from Pierce (Rockford, IL, USA). The human total survivin immunoassay, 
Surveyor IC, was purchased from R&D System (Minneapolis, MN). 
RNase/DNase-free water was obtained from MP Biomedicals (Solon, OH), 
the phosphate saline buffer (PBS) 10× solution and bovine serum albumin 
(Fraction V) were from Fisher Scientific (Fair Lawn, NJ). -tubulin 
antibody (G-8) was from Santa Cruz Biotechnology (Dallas, Texas, USA). 
Fluorescein (FITC)-conjugated AffiniPure Donkey Anti-Mouse IgG (H+L) 
was provided by Jackson ImmunoResearch Laboratories, Inc. (West Grove, 
PA). Hoechst 33342 trihydrochloride, trihydrate, was purchased from 
Molecular Probes (Eugene, Oregon, USA). Vecta Shield mounting medium 
for fluorescence, H-1000, was from Vector Laboratories, Inc. (Burlingame, 
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CA, USA). The RNeasy kit for mRNA isolation was obtained from Qiagen 
(Germantown, MD, USA). The First Strand cDNA synthesis kit and the 
SYBR green kit for qRT-PCR were purchased from Roche, USA. Primers 
for the survivin gene (5’CTGCCTGGCAGCCCTTT-3’) and 
(5’CCTCCAGAAGGGCCA-3’) and for -actin were obtained from 
Invitrogen, CA. The Aspartate aminotransferase (AST)/Alanine 
aminotransferase (ALT) assay kit was purchased from the biomedical 
research service center at SUNY Buffalo (Buffalo, NY, USA). The rabbit 
anti-survivin antibody, AF886, was obtained from R&D System 
(Minneapolis, MN, USA). Texas red-x goat anti-rabbit IgG (T6391) and 
Alexa Fluor 488 goat anti-mouse IgG, IgA, IgM (H+L) were provided by 
Life Technologies (Eugene, Oregon, USA). FragEL DNA fragmentation 
detection kit fluorescent TdT enzyme was provided by EMD Chemicals, 
Inc (San Diego, CA, USA). 
Cell Culture  
Human ovarian cancer cell line (A2780) and human breast cancer cell line 
(MDA-MB231) were cultured in DMEM medium, containing 10% fetal 
bovine serum (FBS), 100 U/mL penicillin G sodium and 100 mg/mL 
streptomycin sulfate (complete medium), in a humidified atmosphere of 
95% air 5% CO2 at 37 °C. Human ovarian cancer cell line sensitive 
(SKOV3) and multi drug resistant (MDR) (SKOV3-tr) were grown in the 
complete RPMI 1640 medium. The SKOV3-tr cells have been widely 
characterized and are known to overexpress the MDR-1 gene (Duan Z. et 
al., 1999).  All the cell lines were obtained from the American Type 
Culture Collection (ATCC, Manassas, VA, USA). Trypan Blue solution 
and trypsin were from CellGro (Kansas City, MO, USA). 
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Synthesis of survivin siRNA-S−S-PE Conjugate  
The survivin siRNA-S−S-PE conjugate was synthesized as previously 
described ( Musacchio T. et al. 2010). Briefly, an aqueous solution of the 
SPDP-activated siRNA (20 nmol in 120 μL of RNase/DNase-free water), 
was added dropwise to a solution of PE-SH (2 μmol) in DMSO and CHCl3 
(total volume of organic solvents 350 μL). The reaction was carried out for 
48 h at room temperature with continuous stirring. The un-reacted reagents 
were removed by desalting column. The collected samples containing the 
survivin siRNA-S-S-PE conjugate were freeze-dried for overnight. After 
freeze-drying, the survivin siRNA-S-S-PE conjugate was hydrated with 
PBS pH 7.4  at a final siRNA concentration of 20 nmol/ml and 
ultracentrifuged for 1 min at 14.5 × 1000 rpm to further remove mixed 
solvents and/or PE-SH. The survivin siRNA-S−S-PE conjugate was stored 
at −20 °C. The conjugation efficiency and the amount of survivin siRNA-
S-S-PE conjugate was determined, after purification, by absorbance at 260 
nm using a Nanodrop (2000c Spectrophotometers, Thermo Scientific).  
Scrambled siRNA was modified following the same protocol. 
Incorporation of siRNA-S−S-PE in PEG2000–PE Micelles  
The PEG2000-PE micelles containing siRNA-S-S-PE were prepared by 
hydration of a thin polymeric film (Salzano G. et al., 2014) . In particular, 
PEG2000-PE was dissolved in chloroform (20 mg/ml) and the resulting 
solution was added to a 50 ml round-bottom flask. The organic solvent was 
removed under reduced pressure by a rotary evaporator under nitrogen 
atmosphere, followed by freeze-drying. Then, the polymeric film was 
hydrated with 1 ml of survivin siRNA-S-S-PE in phosphate buffer at pH 
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7.4 at different PEG2000-PE/siRNA-S-S-PE weight ratio (1:200, 1:500, 
1:750). The resulting dispersion was gently vortexed to form mixed 
micelles, so-called survivin siRNA PM. PEG2000-PE-based PM containing 
scrambled siRNA-S-S-PE and plain PM were prepared similarly. Each 
formulation was prepared in triplicate.   
Preparation and characterization of multifunctional PM co-
encapsulating survivin siRNA and PXL  
PXL was incorporated in survivin siRNA PM as follow. Briefly, an organic 
solution of PXL in methanol (1 mg/mL) was added to the PEG2000-PE 
mixture in chloroform. The initial loading of PXL into micelles was 1% 
w/w. The incorporation of survivin siRNA-S−S-PE into these micelles was 
determined as reported above. The encapsulation efficiency of PXL in PM 
was determined as previously reported (Musacchio T. et al., 2010). For 
imaging studies survivin siRNA/PXL PM contained 0.1% (w/w) of Oregon 
Green labeled PXL were prepared similarly. 
Characterization of PM 
The mean diameter of PM containing survivin siRNA-S-S-PE alone or in 
combination with PXL, was determined at 20°C by the dynamic light 
scattering (DLS) using a Zeta Plus Instrument (Brookhaven Instrument Co., 
Holtsville, NY, USA). Briefly, each sample was diluted in 
deionizer/filtered water and analyzed with detector at 90° angle. As a 
measure of the particle size distribution, polydispersity index (P.I.) was 
used. For each batch, mean diameter and size distribution were the mean of 
three measures. For each formulation, the mean diameter and P.I. were 
calculated as the mean of three different batches. 
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Incorporation of siRNA-S−S-PE Conjugate in PEG2000-PE PM 
The quantitative analysis of siRNA-S-S-PE in PM was performed by the 
size-exclusion high-performance liquid chromatography (SEC-HPLC). For 
the analysis, the HPLC system (D-7000 HPLC, Hitachi, Japan) equipped 
with a Shodex protein KW-804 column (Showa Denko, Japan) and an UV 
detection at 280 nm, was used. The mobile phase was composed of 50 mM 
NaCl and 50 mM Tris-HCl (pH 8.0) and the flow rate at 1.0 mL/min. The 
siRNA-S-S-PE loading efficiency into PM was evaluated by ratio of the 
area under the peaks at the same retention time (tr ca. 10 min) of survivin 
siRNA-S-S-PE not encapsulated in PM and the survivin siRNA-S-S-PE 
initially added to the PM. As a control, plain PM were also analyzed. To 
confirm the data collected by SEC-HPLC, we analyzed the same samples 
also by the reverse phase HPLC (RP-HPLC). The RP-HPLC analysis was 
carried out as previously reported (Musacchio T., et al., 2010). Then, we 
evaluated the loading efficiency of PXL in survivin siRNA PM. The 
quantitative analysis of PXL was determined by RP-HPLC as previously 
reported (Musacchio T. et al., 2009), using a XBridge column 
(4.6mm×250mm, Waters, Milliford, USA). The mobile phase consisted of 
water and acetonitrile with volume ratio 60:40, the elution was performed 
at a rate of 1.0 ml/min, and PXL was detected from injected sample (50μL) 
at 227nm. 
Cell viability assay 
A2780, MDA-MB 231, SKOV3 and SKOV3-tr cells were seeded at a 
density of 3 × 10
3
 cells/well in 96-well culture plates for 24 h. After 24 h, 
the cells were treated with various concentrations of survivin siRNA-S−S-
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PE free or in PM, scrambled siRNA-S-S-PE in PM and plain PM, in serum-
contained media. The final concentration of siRNA-S-S-PE was in the 
range of 200 to 17.6 nM. After 6 h, the medium was replaced with fresh 
medium, and the cells were incubated until the 48-hour-time point was 
reached. Cells without treatment were used as control. The cell viability 
was determined by Cell Titer Blue assay following manufacturer’s 
protocol. The experiments were done in triplicate on three different sample 
preparations. 
Survivin Protein Assay 
A2780, MDA-MB231, SKOV3 and SKOV3-tr cells (3·104 cells per well) 
were seeded into 48-well plates. Cells were treated with survivin siRNA 
PM at a final concentration of 200 nM in serum-containing medium for 6 h. 
Cells were washed once with fresh medium and maintained in fresh 
medium until 48 h. Cells were rinsed three times with PBS and treated with 
200 l of cold lysis buffer for 30 minutes on ice (R&D system). Cell 
lysates were collected, vortexed, and incubated on ice for other 15 minutes 
twice. Cell debris was removed by centrifugation at 2000g for 5 min, and 
protein concentrations were determined by BCA assay after 6-fold dilution 
in PBS. Samples were added into captured antibody pre-coated 96-well 
plates, and human survivin was assayed by ELISA after 6-fold dilution in 
assay buffer (R&D system). 
Chemosensitization Study 
MDA-MB231, SKOV3 and SKOV3-tr cells (3·103 per well) were seeded 
into 96-well plates. Cells were treated with survivin siRNA PM at the 
concentration of 200 nM for 6 h. After 6 h, the medium was replaced with 
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fresh medium, and the cells were incubated for another 48 h. Cells were 
then exposed to different concentrations of PXL for 24 h.  Cell viability 
was detected by the Cell Titer Blue assay. 
Immunohistochemical staining 
SKOV3-tr cells (2·104 per coverslip) were seeded and grown on glass 
coverslips coated with 1% gelatin cross-linked with 0.5% glutaraldehyde in 
a 12-well plate. After 24 h, cells were treated with 200 nM of survivin 
siRNA PM for 6 h. After 6 h, the medium was replaced with fresh medium, 
and the cells were incubated for another 48 h. Then, cells were exposed to 
40 nM of free PXL for 24 h. As controls, free PXL (40 nM), survivin 
siRNA PM, and untreated cells were used. Cells were washed three times 
with PBS and then were fixed with 4% paraformaldehyde. Fixed cells were 
made permeable with 0.2% Triton X-100 in PBS and incubated with a 
monoclonal antibody against -tubulin (1:10) for 1 h in 1% bovine serum 
albumin/PBS. After washing, cells were incubated with a secondary FITC-
labeled mouse-immunoglobulin G targeting antibody (1:100) for 1 h in 1% 
bovine serum albumin/PBS. After washing, cells were incubated with 
Hoechst 33342 (5 M) for nuclear staining. The coverslips were mounted 
on glass slides with Fluoromount-G (Fisher Scientific,Waltham, MA) 
medium and sealed using a nail lacquer. The slides were observed with a 
Zeiss LSM 700 inverted confocal microscope (Carl Zeiss Co. Ltd., Jena, 
Germany) equipped with a 63x, 1.4-numerical aperture plan-apochromat 
oil-immersion objective. The images were analyzed using the ImageJ 
version 1.42 software (NIH, Bethesda, MD).  
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In vitro cytotoxicity of PM co-loaded with the combination of survivin 
siRNA-S-S-PE and PXL 
SKOV3-tr cells (3·103 cells/well) were seeded in 96-well plates.  After 24 h 
the cells were treated with different concentrations of survivin siRNA/PXL 
PM for 6 h in serum contained media.  After 6 h, the medium was replaced 
with fresh medium, and the cells were incubated for another 72 h. Same 
concentrations of free PXL, survivin siRNA PM, and scrambled siRNA 
PM were used as controls. The cell viability was assessed by the Cell Titer 
Blue assay. 
In vivo studies: Cell Culture  
Human ovarian adenocarcinoma cell line, MDR SKOV3-tr, was obtained 
from the American Type Culture Collection (ATCC, Manassas, VA, USA). 
The cells were grown in RPMI®-1640 medium supplemented with 10% 
(v/v) fetal bovine serum (FBS), and 100 U/mL penicillin G sodium and 100 
mg/mL streptomycin sulfate (complete medium), in a humidified 
atmosphere of 95% air 5% CO2 at 37 °C. The SKOV3-tr cells have been 
widely characterized and are known to over express the MDR-1 gene 
(Duan Z. et al., 1999). For the subculture, cells growing as monolayer were 
detached from the tissue flasks by treatment with trypsin/ EDTA. The 
viability and cell count were monitored routinely using trypan blue dye 
exclusion method. The cells were harvested during the logarithmic growth 
phase and re-suspended in serum free medium before inoculation in 
animals. 
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Experimental model  
The experimental protocol involving use of animals was approved by the 
Institutional Animal Care and Use Committee of Northeastern University. 
SCID female nude mice (nu/nu), 6-8 weeks old and weighing 20-25 g were 
purchased from Charles River Laboratories (Cambridge, MA) and were 
housed under controlled laboratory conditions in polycarbonate cages. The 
animals were allowed to acclimate for at least 48 hr before any experiment. 
Subcutaneous tumor xenografts development 
Approximately, 7 million of SKOV3-tr cells, suspended in 100 l of 
Matrigel® (in free serum media 1:1 volume ratio), were injected 
subcutaneously into the left flank of mice under light isoflurane anesthesia. 
Palpable solid tumors developed within 15 days post tumor cell inoculation 
and as soon as tumor volume reached 150-200 mm
3
, the animals were 
randomly allotted to 5 different controls and treatment groups [i.e., PBS, 
PXL in Cremophore EL1-ethanol (1:1) mixture with normal saline (Taxol),  
PM containing scrambled siRNA-S-S-PE conjugate and PXL in 
combination (scrambled siRNA/PXL PM), PM containing survivin siRNA-
S-S-PE conjugate (survivin siRNA PM) and PM containing survivin 
siRNA-S-S-PE and PXL in combination (survivin siRNA/PXL PM). Six 
animals per group were used for the experiment. All controls and micelle 
formulations were diluted and suspended in sterile PBS.  Each tumor-
bearing animal received siRNA-S-S-PE at a dose of 20 g, corresponding 
to 1mg/kg per injection, and PXL at a dose 10 mg/kg both in Cremophore 
solution or in PM by intravenous administration through the tail vein once 
per week for 5 consecutive weeks. 
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Evaluation of therapeutic efficacy 
The tumor diameters were measured three times weekly with a vernier 
calipers in 2 dimensions. Individual tumor volumes (V) were calculated 
using the formula (Tomayko M.M. et al., 1989): 
V = [length x (width)2]/2  
where length (L) is the longest diameter and width (W) is the shortest 
diameter perpendicular to length. 
Growth curves for groups of tumors are presented as the Relative Tumor 
Volume (RTV), defined as Vn/Vo, where Vn was the tumor volume in 
mm3 on day ‘n’ (Vn) and Vo at the start of the treatment plotted versus 
time in days. Mean RTV (mRTV) and standard deviation were calculated 
per each group. At the end of the experiment, the animals were killed by 
cervical dislocation and the tumor mass was harvested and weighed.  
Evaluation of repeated dose toxicity in mice 
For safety evaluation of the controls and survivin siRNA/PXL PM 
formulation, the body weight of each mouse was determined three times 
per week and related to the first day as percent change in body weight. In 
addition, blood samples were collected via cardiac puncture before the time 
of sacrifice and the levels of serum aspartate amino transferase (AST) and 
alanine amino transferase (ALT) were measured. In particular, the serum 
was obtained by centrifugation of the freshly collected blood samples at 
2,000 x g for 30 min at 4°C. Then, AST and ALT were measured using the 
manufacturer’s standard kinetic assay protocol (Biomedical Research 
Service).  
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Collection of Tumor Tissues 
Tumors were excised, dissected free of the skin and body tissue and 
weighed on a digital balance. Then, the tumors were immediately snap-
frozen in liquid nitrogen and maintained at -80˚C until ready for sectioning. 
For immunofluorescence analysis, frozen sections (6 μm) were cut on a 
Cryostats microtome (Thermo Scientific), placed on glass slides and stored 
at -20˚C until they were used. 
Tumor cell apoptosis 
Tumor sections were stained by Hoechst 33342, and the tumor cell 
apoptosis was analyzed by terminal deoxynucleotidyl transferase dUTP 
nick end labeling assay using a FragEL DNA Fragmentation Detection Kit, 
according to the protocol described by the supplier. The pictures were 
taken by confocal microscopy. The slides were visualized by light 
microscopy at 40× magnification. 
Evaluation of survivin mRNA expression by using RT-PCR.  
Survivin mRNA expression was assayed by performing real-time PCR 
from different tumor tissues. Tumors were vortexed in a 50mL tube 
containing 1 mL of cold PBS. Total RNA was isolated from the cells using 
the RNeasy mini kit (Qiagen) according to the manufacturer’s instructions. 
cDNA was synthesized from 250 ng of total RNA primed with a random 
hexamer using the Superscript First-Strand System (Invitrogen). For the 
experiment we used the following survivin primer sequence: human 
survivin: (forward) 5’-CTGCCTGGCAGCCCTTT-3’ and (reverse)  5’-
CCTCCAAGAAGGGCCAGTTC-3’ (Nakahara T. et al., 2007).  Real-time 
63 
 
PCR was done using the ABI Prism 7900 sequence detection system and 
the SYBR Green PCR Master Mix (Applied Biosystems) according to the 
manufacturer’s instructions. Dissociation curve analyses were done to 
verify that there was neither unspecific amplification nor formation of 
primer dimers. Values were calculated based on standard curves generated 
for each gene. Normalization of samples was determined by dividing 
copies of survivin transcripts by copies of actin. All sets of reactions 
were conducted in triplicate. The relative expression levels are expressed as 
a percentage of the indicated control. 
Determination of survivin protein expression by immunofluorescence 
analysis 
Survivin immunofluorescence analysis was performed on frozen tumor 
sections. In detail, tumor sections were fixed with 4% of paraformaldehyde 
for 20 min at room temperature. After twice washing with PBS, slides were 
immersed in 0.5 % of H2O2/PBS solution at room temperature for 10 min to 
block endogenous peroxidase activity. The slides were rinsed in PBS 
solution for two changes, 5 min each, and then, incubated in 1% of Triton 
X-100 solution for 10 min. Enzymatic activity and non-specific binding 
sites were blocked by incubating the slides in 10% of FBS for 1 hour at 
room temperature in a humidified chamber. Subsequently, replicate 
sections were incubated at 4˚C overnight with a primary rabbit anti-
survivin antibody (AF886; R&D System) at a final concentration of 10 
g/ml. Thorough rinsing was followed by incubation with red-fluorescent 
dye-labeled anti-rabbit IgG (10 g/ml; T6391; Life Technologies) for 1 
hour.  Negative controls for each tissue section were performed leaving out 
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the primary antibody. Finally, the nuclei were stained with Hoechst 33342 
(5 M) for 15 min at room temperature and the stained sections were 
observed and photographed using a Nikon Eclipse E400 microscope and a 
Spot Advanced software (Spot Imaging).  
Evaluation of the simultaneous intra-tumor accumulation of PXL and 
down-regulation of survivin expression in tumor sections  
For this experiment, mice (n=3) were injected once with survivin 
siRNA/PXL PM. After 48 hours the animals were injected with survivin 
siRNA/PXL PM containing Oregon Green labeled PXL (0.1% w/w). After 
1 hour the animals were sacrificed. Tumors were excised and processed as 
above under light protection. At the same time, the intra-tumor 
accumulation of Oregon Green labeled PXL and  survivin protein 
expression were evaluated. The survivin protein expression was evaluated 
by immunofluorescence analysis, as reported above. The nuclei were 
stained with Hoechst 33342. Negative control, such as untreated tumor 
sections and sections exposed to the secondary antibody only, were 
processed as described above. Images were recorded by confocal 
microscopy.  
Tubulin immunostaining 
Frozen sections were processed as above and incubated with a monoclonal 
antibody against -tubulin (G-8; Santa Cruz Biotechnology; dilution 1:50) 
for overnight at 4˚C. After washing, sections were incubated with a 
secondary Alexa Fluor 488-labeled goat anti-mouse IgG targeting antibody 
(dilution 1:100) for 1 hour at room temperature. Then, after washing, 
sections were incubated with Hoechst 33342 (5 M) for nuclear staining. 
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The slides were mounted on glass slides with Fluoromount-G (Fisher 
Scientific,Waltham, MA) medium and sealed using a nail lacquer. Negative 
control sections were exposed to the secondary antibody only and 
processed as described above. The slides were observed with a Zeiss LSM 
700 inverted confocal microscope (Carl Zeiss Co. Ltd., Jena, Germany) 
equipped with a 63x, 1.4-numerical aperture plan-apochromat oil-
immersion objective. The images were analyzed using the ImageJ version 
1.42.  
Statistical analysis 
For comparison of several groups, one-way ANOVA for multiple groups, 
followed by Newmane-Keuls test if P < 0.05 was performed using 
GraphPad Prism version 5.0 software (GraphPad Software, Inc, San 
Diego,CA). All numerical data are expressed as mean ± SD, n = 3 or more, 
from 3 different experiments. Any p values less than 0.05 was considered 
statistically significant. 
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Results 
Synthesis and characterization of survivin siRNA PM  
In this study, we proposed a new strategy to stabilize and deliver siRNA 
against survivin into cancer cells.  As the first step, we synthesized a 
survivin siRNA conjugated with a phospholipid (PE-SH) with the disulﬁde 
linkage at the 3′-end of the modiﬁed siRNA SPDP sense strand. The yield 
of the conjugation reaction between siRNA and PE was ~90%. Survivin 
siRNA-S-S-PE conjugate was then incorporated in PM. We have optimized 
the weight ratio (siRNA conjugate to PEG2000-PE to the micelle-forming 
component) required to obtain PM with narrow size distribution and high 
siRNA-S-S-PE incorporation efficiency. More specifically, we prepared 
PM at a survivin siRNA-S-S-PE/PEG2000-PE weight ratio of 1:200, 1:500 
and 1:750, respectively. As reported in Table I, at the ratios tested, the PM 
were characterized with mean diameter of ~20 nm and a narrow size 
distribution, with a P.I. ≤ 0.2.  
Formulations 
(weight ratio) 
Mean 
Diameter 
 (nm ± SD) 
P.I. ± SD 
Survivin siRNA 
incorporation 
efficiency (% ± SD) 
Survivin siRNA PM 
(1:200) 
18.7 ± 3.5 0.191 ± 0.08 26.0 ± 5.0 
Survivin siRNA PM 
(1:500) 
18.3 ± 2.0 0.189 ± 0.06 31.0 ± 3.8 
Survivin siRNA PM 
(1:750) 
21.5 ± 3.3 0.160 ± 0.05 52.0 ± 1.6 
Table I. Physical characteristics of survivin siRNA PM. 
The incorporation efficiency of survivin siRNA-S-S-PE in PM was 
determined by SEC-HPLC. After injection of survivin siRNA PM, SEC-
HPLC analysis demonstrated that the peak at ca. 8 min corresponded to PM 
containing survivin siRNA, while the peak at ca. 10 min corresponded to 
free siRNA-S-S-PE (Figure 2). Plain PM analyzed at the same 
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concentration as survivin siRNA PM showed the same peak as PM 
containing survivin siRNA at ca. 8 min. Therefore, we calculated the 
survivin siRNA incorporation efficiency by the ratio of free survivin 
siRNA-S-S-PE, not incorporated in PM, and survivin siRNA-S-S-PE 
initially added to micelle-forming components.  
 
Figure 2. Incorporation efficiency of the modified siRNA into PM determined by 
SEC. The degree of the incorporation efficiency was measured by ratio of the area 
under the peak of free survivin siRNA-S-S-PE, not incorporated in PM, and the siRNA-
S-S-PE initially added to PM at the same retention time (tr ca. 10 min). As a reference, 
plain PM were used. 
As shown in the Table I, the highest loading efficiency, about 50%, was 
reached only with PM prepared with the highest amount of polymer, 
namely with a weight ratio of 1:750. These data were confirmed by RP-
HPLC using previously described methods (Salzano G. et al., 2014)  (data 
not shown). This formulation was selected for the subsequent studies.  
In the following step, the co-encapsulation of survivin siRNA-S-S-PE and 
PXL in PM was investigated. In particular, the attention was focused on the 
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effect of PXL on the physical characteristics of PM, i.e. size and siRNA-S-
S-PE loading efficiency. As reported in the Table II, when PXL was added 
to survivin siRNA PM, no change in the size and in the loading efficiency 
was observed. In particular, survivin siRNA/PXL PM had a mean diameter 
of about 22 nm with narrow size distribution (PI< 0.2). Chromatographic 
analysis of non-encapsulated survivin siRNA-S-S-PE and PXL showed an 
encapsulation efficiency of about 50% and 70%, respectively. 
Formulations 
Mean 
Diameter  
(nm ± SD) 
P.I. ± SD 
Survivin siRNA 
incorporation 
efficiency (% ± SD) 
PXL incorporation 
efficiency  
(% ± SD) 
Survivin siRNA PM 21.5 ± 3.3 0.160 ± 0.05 50.0 ± 1.0 - 
Survivin siRNA/PXL PM 25.0 ± 3.6 0.190 ± 0.07 51.0 ± 1.5 69.9 ± 2.5 
 
Table II. Physical characteristics of PM co-loaded with survivin siRNA-S-S-PE and 
PXL. 
Effect of survivin siRNA PM on the viability of cancer cell lines 
The effect of survivin siRNA-S-S-PE incorporated in PM on the growth of 
different human cancer cell lines, namely breast (MDA-MB231), ovarian 
(A2780, SKOV3), and paclitaxel-resistant ovarian cell (SKOV3-tr), was 
investigated by the Cell Titer Blue assay. In the Figure 3, the cell viability 
(%) after treatment with 200 nM of survivin siRNA-S-S-PE in PM in the 
different cell lines analyzed after 48 h, is reported. In all sensitive cell lines, 
when considering survivin siRNA-S-S-PE incorporated in PM, we found a 
significant (p<0.001 survivin siRNA PM versus the other treatments) anti-
proliferative effect. The highest cell growth inhibition was observed in 
ovarian cancer cells, especially in A2780, reaching a reduction of cell 
viability of about 70%. No toxicity of PM or micelles prepared with 
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irrelevant siRNA was observed indicating the effect was mediated by 
RNAi toxicity, which corresponds to earlier mentioned data (Sawant R.R. 
et al., 2010). In PXL-resistant SKOV3-tr cells however, no significant 
reduction of the cell viability was found under the action of siRNA-
containing micelles. 
 
Figure 3. Viability of different cancer cells. Cells were treated with survivin siRNA 
PM at a final siRNA concentration of 200 nM in the serum-containing medium for 6 h. 
Cell viability in the presence of survivin siRNA PM, free survivin siRNA-S-S-PE 
conjugate,  PM containing scrambled siRNA-S-S-PE, and plain PM was followed by 
Cell Titer Blue assay after 48 h of incubation. **p < 0.01, and ***p < 0.001 values were 
obtained by comparing survivin siRNA PM to all the other treatments. Results were 
obtained from three independent experiments in triplicate (n = 9). Mean ± SD. 
Survivin protein levels 
Survivin protein levels in the cells treated with survivin siRNA-S-S-PE in 
PM were then evaluated by ELISA. As illustrated in Figure 4, after 
treatment with PM containing survivin siRNA-S-S-PE, a significant down-
regulation of survivin, by about 30% (p<0.01 survivin siRNA PM versus 
the other treatments), was observed in all the cell lines. Noteworthy, a 
significant down-regulation (by about 30%) of survivin levels was 
observed also in survivin over-expressing SKOV3-tr cells. In cells treated 
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with free survivin siRNA-S-S-PE, and with PM containing scrambled 
siRNA-S-S-PE, no significant decrease of survivin level was observed.  
 
Figure 4. Survivin protein levels in A2780, MDA-MB231, SKOV3, and SKOV3-tr 
cells after different treatments. Survivin siRNA was quantified 48 h after the 
treatment by the ELISA method. The data are expressed as ng of survivin protein per 
mg of protein. Data = mean ± SD (n =3). **p < 0.01, and ***p < 0.001 values were 
obtained by comparing survivin siRNA PM to all the other treatments. Results were 
obtained from three independent experiments in triplicate (n = 9). Mean ± SD. 
Chemosensitization study 
In order to evaluate whether the down-regulation of survivin resulting from 
the treatment with survivin siRNA PM is able to sensitize cells to PXL, 
chemosensitization studies were performed. In particular,  survivin siRNA 
PM pre-treated MDA-MB-231, SKOV3 and SKOV3-tr cells were exposed 
to increasing concentrations of PXL, and the resultant cell viabilities are 
summarized in Figures 5 a, b and c, respectively. As detailed in Figure 5, in 
all the cell lines tested, no toxicity was detected with free PXL at a dose 
range from 40 nM to 3.5 nM after 24 h of treatment. Increasing the 
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incubation time to 72 h lead to significant toxicity in PXL-sensitive cell 
lines whereas none was detected in SKOV3-tr, using the same range of 
concentrations (data not shown). Confirming our initial hypothesis, the 
down-regulation of survivin by pre-treatment of the cells with survivin 
siRNA PM, strongly sensitized the cells to PXL. In particular, a significant 
increase of the PXL cytotoxicity was observed after only 24 h of cell 
exposure to the drug (Figure 5). These results were confirmed by the 
immunofluorescence analysis.  
 
Figure 5. Chemosensitization of MDA MB-231(A), SKOV3 (B), and SKOV3-tr (C) 
cells mediated by the pre-treatment with survivin siRNA PM. Cells were incubated 
with survivin siRNA PM (range of siRNA concentrations from 200 to 17.5 nM) for 6 h. 
Forty eight hours later, cells were challenged with various concentrations of PXL. The 
viability of cells was measured 24 h later by the CTB assay. Data = mean ± SD (n 
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=3).**p < 0.01, and ***p < 0.001 values were obtained by comparing survivin siRNA 
PM pre-treated cells (survivin siRNA PM) to PXL no pre treated cells (no pre-
treatment). 
Figure 6 shows the influence of the pre-treatment with survivin siRNA PM 
on the PXL activity in microtubules stabilization in the resistant cancer cell 
line, SKOV3-tr. In untreated cells, in cells treated for 24 h with 40 nM of 
PXL and cells treated with survivin siRNA PM for 48 h (Figure 6 A,B,C, 
respectively), microtubules appear “healthy” with elongated and fibrillary 
extensions from around the nucleus to the cell periphery. In contrast, the 
down regulation of survivin mediated by pre-treatment with survivin 
siRNA PM for 48 h, sensitize SKOV3-tr cells to PXL action on 
microtubule organization (Figure 6D). Here, microtubules appear 
disassembled and characterized by a loss of fibrillar extensions as 
confirmed by the dense organization of microtubule network around the 
nucleus. The nuclei begin to fragment, reflective of cell death.  These 
results confirm that survivin down-regulation enhances the PXL activity in 
microtubule destabilization.  
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Figure 6. Effect of PXL on microtubule stabilization after survivin down-
regulation in SKOV3-tr cells. SKOV3-tr cells were pre-treated with 200 nM survivin 
siRNA PM for 48 h followed by the treatment with 40 nM of PXL for 24 h. Cells were 
then stained for -tubulin (green). The nuclei (blue) were stained with DAPI. A-D: 
Representative images of three independent experiments showing organization of 
microtubules. Untreated cells (A); cells treated with free PXL for 24h (B); cells treated 
with survivin siRNA PM for 72 h (C); cells pre-treated with survivin siRNA PM for 48 
h followed by treatment with PXL for 24 h (D). Data = mean ± SD (n =3). 
Multifunctional therapy: survivin siRNA-S-S-PE and PXL co-
encapsulated in PM  
Finally, we investigated the effect of survivin siRNA-S-S-PE and PXL co-
loaded in PM on the viability of a PXL-resistant cancer cell line, SKOV3-
tr. For this purpose, we studied the effect of increasing concentrations of 
survivin siRNA-S-S-PE and PXL co-encapsulated in PM on the cell 
viability. In Figure 7, the viability of SKOV3-tr cells (%) 72 h after the 
treatment with free PXL, survivin siRNA PM and survivin siRNA/PXL 
PM, is shown. After the treatment with free PXL, no significant inhibition 
of the cell growth was observed. On the contrary, the simultaneous delivery 
of PXL and survivin siRNA-S-S-PE by PM to SKOV3-tr cells lead to a 
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significant inhibition of cell growth compared to all other treatments 
(p<0.001 survivin siRNA/PXL PM versus the other treatments). 
 
Figure 7. The viability of SKOV3-tr cancer cells. The cells were treated with the 
different formulations at 37°C for 6 h. After 72 h, the cell viability was measured by the 
Cell Titer Blue assay. Data = mean ± SD (n =3). ***p < 0.001 values were obtained by 
comparing each treatment to survivin siRNA/PXL PM treated cells. 
Therapeutic efficacy of survivin siRNA/PXL PM on an animal model 
of PXL resistant ovarian cancer, SKOV3-tr. 
Since in SKOV3-tr cell lines, the simultaneous delivery of PXL and 
survivin siRNA by using PM strengthens significantly the cytotoxicity 
induced by free or micellar PXL, the antitumor efficiency of such 
combination was investigated  in an animal model of SKOV3-tr xenografts. 
To this purpose immune-suppressed mice were injected with SKOV3-tr 
cells and starting from day 15 treated with Taxol, scrambled siRNA/PXL 
PM, survivin siRNA PM and survivin siRNA/PXL PM once a week for 
five consecutive weeks. The anti-tumor efficacy was assessed by 
evaluation of the relative tumor volume (RTV) during therapy and the post-
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mortem tumor weights. As reported in Figure 8A, PXL by itself, both in 
Cremophore solution (Taxol) and incorporated in PM (scrambled 
siRNA/PXL PM), did not induced a significant effect in the tumor growth. 
On the contrary, following the treatment of the animals with PM containing 
survivin siRNA alone or in combination with PXL the therapeutic outcome 
changed dramatically. Surprisingly, on the contrary to what observed 
previously in vitro in SKOV3-tr cell lines (Salzano G. et al., 2014), the 
treatment with survivin siRNA alone was able to induced a significant 
slowing of the tumor growth. This effect was even more pronounced in 
survivin siRNA/PXL PM treated group. In particular, the treatment of mice 
with the combination elicited a marked antitumor activity, showing the 
least RTV among all the treatment groups (P < 0.05). Moreover, the tumor 
weights of mice treated with this schedule, evaluated after sacrifice the 
animals, was significantly reduced compared to all the control groups (P < 
0.01) (Figure 8B).  None of the agents caused any over toxicity, we did not 
detect significant changes in body weight (Figure 8C), toxic adverse events 
or deaths, confirming low non-specific toxicity of the treatments. To 
monitor the general toxicity after repeated doses of the treatments, the 
serum levels of ALT and AST were measured. As reported in Table III, 
there was no significant decrease of ALT and AST levels in serum 
following all the treatment groups, suggesting the absence of liver toxicity 
induced by the treatments. 
 
 
 
76 
 
Treatments AST (IU/L) ALT (IU/L) 
PBS 10.44 ± 0.14 24.33 ± 0.13 
Taxol 9.37 ± 0.34 18.17 ± 0.13 
Scrambled siRNA/PXL PM 10.17 ± 0.18 19.64 ± 0.29 
Survivin siRNA PM 11.21 ± 0.06 19.01 ± 0.08 
Survivin siRNA/PXL PM 9.94 ± 0.52 18.27 ± 0.31 
 
Table III. Evaluation of repeated dosing toxicity in mice by measurement of 
changes in serum levels of transaminase (AST/ALT).  
 
Figure 8 A. In vivo antitumor activity of survivin siRNA/PXL PM in SKOV3-tr 
xenografts. Survivin siRNA/PXL PM were administered at a final concentration of 
anti-survivin siRNA and PXL of 1 and 10 mg/kg, respectively, once per week for 5 
consecutive weeks. Relative tumor volume (RTV) values (Tumor volume in mm3 on 
day ‘n’ (Vn) / tumor volume at the start of the treatment (Vo) plotted versus time in 
days) are reported. Data were given as mean ± SD for each treatment group. *p < 0.05, 
**p < 0.01, and ***p < 0.005  were obtained by comparing each treatment group with 
Taxol group. 
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Figure 8 B. Post-mortem tumor weights. On day 30, eterotopically implanted tumors 
were weighed and plotted. *p < 0.05 and **p < 0.01 were considered significant and 
very significant, respectively, and were obtained by comparing each treatment group 
with survivin siRNA/PXL group. 
 
 
Figure 8C. Body weight of nude mice bearing SKOV3-tr measured every 3 days 
during the study. P values were considered no significant (N.S.) and were obtained by 
comparing each treatment group with survivin siRNA/PXL group. 
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Tumor tissues apoptosis 
In order to investigate the biochemical mechanisms on the basis of the 
inhibition of the tumor growth in mice treated with survivin siRNA/PXL 
PM, the apoptotic effect was evaluated. Tumor sections of tumors dissected 
from the previous experiment were stained by Hoechst 33342, and 
apoptosis was analyzed by TUNEL assay under confocal microscopy. As 
shown in Figure 9, the co-delivery of PXL and survivin siRNA leads to the 
highest rate of cell apoptosis (Figure 9E), which was clearly superior to all 
the other treatment groups.  
 
Figure 9. Apoptosis analysis on tumor sections by TUNEL assay. Pictures were 
taken by confocal microscopy (40x magnification). The nuclei were stained for Hoechst 
and apoptotic cells (green) for Tunel. Representative images of (A) Untreated, (B) 
Scrambled siRNA/PXL PM,(C) Taxol, (D) Survivin siRNA PM, (E) Survivin 
siRNA/PXL PM groups. 
Down-regulation of survivin mRNA expression in vivo 
To provide evidence that the inhibition of the tumor growth by using 
survivin siRNA/PXL PM was due to its ability to down-regulate survivin in 
vivo, transcriptional mRNA of survivin gene expression was evaluated in 
tumor tissues by RT-PCR. Experiments were repeated three times. The 
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relative levels of survivin mRNA in tumor tissues were normalized against 
mRNA of an internal control gene, -actin, performed in the same run 
(Wang Z. et al., 2005). As shown in Figure 10, the relative levels of 
survivin mRNA in mice treated with survivin siRNA/PXL PM (0.09±0.03) 
was significantly decreased compared with untreated (0.99±0.007) and 
scrambled siRNA/PXL PM (0.86±0.05) animal groups. The co-delivery of 
anti-survivin siRNA and PXL showed an inhibitory rate of survivin mRNA 
of about 90%. Interestingly, the treatment with Taxol could also reduce the 
survivin expression in tumors (Figure 10). In according with those 
previously reported by Hu Q. et al., (2012), PXL free, as a result of mitosis 
inhibition, reduced temporarily the expression of survivin. These results 
indicated that the combination of an anti-survivin siRNA with a 
chemotherapeutic agent, such as PXL, with effective silencing propriety on 
survivin expression, could be a powerful approach to treat MDR tumors.  
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Figure 10. Survivin mRNA levels in tumor tissues by rt-PCR analysis. Data were 
given as mean ± SD for each treatment group. **p < 0.01, ***p < 0.005  were obtained 
by comparing each treatment group with survivin siRNA/PXL group. 
Espression  of survivin protein detected by immunofluorescence analysis  
In order to confirm the data obtained by RT-PCR analysis, protein levels of 
survivin in tumor xenografts were investigated by immunohistochemical 
analysis. As shown in Figure 11A, the microscopic examination of stained 
tumor sections showed strong immunoreactivity for survivin (red color) in 
untreated and scrambled siRNA/PXL PM groups. In contrast, the intensity 
of survivin signal was dramatically decreased in survivin siRNA PM and 
survivin siRNA/PXL PM treated groups. Furthermore, the simultaneous 
delivery of PXL and gene in tumors was examinated by confocal laser 
scanning microscope. For confocal microscopy observation, 
immunostaining for survivin, as described above, was used to evaluate the 
gene silencing and Oregon Green labeled PXL was used to follow the drug. 
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In particular, mice were treated once with survivin siRNA/PXL PM. After 
48 hours the animals were injected with survivin siRNA/PXL PM 
containing Oregon Green labeled PXL. One hour later, the animals were 
sacrificed and tumors sections were processed under light protection. The 
confocal microscopy study showed clearly that Oregon Green labeled PXL 
was transported in the tumor tissues and survivin was significant down-
regulated (Figure 11B). It is interesting to note that, a single administration 
of survivin siRNA/PXL PM was able to efficiently down-regulate survivin 
expression in tumors, as suggested by the almost absence of the survivin 
red signal in the sections.   
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Figure 11 A. Immunohystochemistry analysis: Survivin protein levels was evaluated 
by fluorescent microscope (50 x). Representative images of three independent 
experiments showing survivin expression (in red). Untreated group (A); Scrambled 
siRNA/PXL PM group (B); Taxol group (C); Survivin siRNA PM group (D); Survivin 
siRNA/PXL PM group (E). Scale bar 5 m. 
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Figure 11 B. Simultaneous down-regulation of survivin expression and PXL 
penetration in tumor tissues by using survivin siRNA/PXL PM (63x). At the same 
time, the intra-tumor accumulation of Oregon Green labeled PXL (left) and survivin 
protein expression (middle) were evaluated on tumor sections by confocal microscopy 
(magnification 63x). Scale bar 5 m. 
Effect of survivin siRNA/PXL PM on microtubule conformation of 
ovarian cancer xenografts 
Previously, we have shown that survivin down-regulation enhanced the 
PXL activity on microtubule organization in SKOV3-tr cells. In particular, 
after down-regulation of survivin levels by treating cells with survivin 
siRNA PM, PXL was able to destabilize the microtubule organization at a 
very low concentration and exposition time. Here, to assess the effect of 
survivin siRNA/PXL PM on microtubule organization in vivo, SKOV3-tr 
tumor sections were incubated with an anti-tubulin fluorescent antibody. 
As shown in Figure 12A, in untreated mice, tumor cells exhibited staining 
of elongated microtubule fibers, demonstrative of an intact microtubule 
network. No significant difference were observed in all the other control 
groups (Figure 12 B-C-D).  Interestingly, survivin siRNA/PXL PM group 
showed a microtubule-staining organization that was markedly different 
from all the other treatments (Figure 12E). In particular, as indicated by the 
arrows, in survivin siRNA/PXL PM treated mice, the tumor cells exhibited 
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diffuse and separate dense organization of microtubules in all the tissue 
(Figure 12 E). This results can be demonstrative of a no intact microtubule 
network. 
 
Figure 12. Microtubule organization after treatment with survivin siRNA/PXL PM 
in vivo. SKOV3-tr tumor sections were stained for -tubulin (green). The nuclei (blue) 
were stained with Hoechst. A-E: Representative images of three independent 
experiments showing organization of microtubules. Untreated group (A); scrambled 
siRNA/PXL PM group (B); Taxol group C); survivin siRNA PM group (D); survivin 
siRNA/PXL PM group (E). Data = mean ± SD (n =3). 
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Discussion 
Survivin, a member of the IAP family, is considered a challenging target 
for cancer therapy. Survivin, not usually detected in normal adult tissue, is 
over-expressed in malignant tumors where plays a key role in hampering 
apoptosis, promoting cell proliferation, mitosis and angiogenesis (Altieri 
D.C. et al., 2008). Moreover, there is evidence that survivin up-regulation 
may be a predictive factor in determining drug-resistance. Interestingly, it 
has been demonstrated that survivin inhibition reduces tumor growth 
potential and markedly enhances tumor cell response to anticancer agents, 
such as PXL, etoposide, cisplatin (Zaffaroni N. et al., 2002), as well as to 
immunotherapy and ionizing radiation (Kanwar J.R. et al. 2001, Sah N.K. 
et al., 2006). The resounding demonstrations of the efficacy of survivin 
inhibition in pre-clinical experiments has strongly incited to develop new 
strategies to target survivin in human tumors. Recently, siRNA directed 
against survivin, has been proposed as valid approach to specifically 
suppress survivin in cancer cells. In fact, it was shown to sensitize and 
strengthen the tumor response to chemotherapeutic drugs (Shapira A. et al., 
2011). However, the major obstacle to therapeutic RNAi is the 
disadvantageous biopharmaceutical profile, which strongly hampers 
achieving effective concentrations in intracellular site of action. Therefore, 
delivery strategies that stabilize siRNA and enhance intracellular uptake in 
vivo need to be developed. 
A new method addressed to stabilize and deliver the siRNA was 
recently proposed by Prof. Torchilin V.P. group. In particular, a siRNA 
“reversibly” conjugated to a phospholipid by a disulfide linkage was 
synthesized (Musacchio T. et al., 2010). The resulting modified siRNA was 
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incorporated in nanosized PEG2000-PE PM via its hydrophobic lipid moiety. 
As a result, the stability of PM-incorporated siRNA against nucleolytic 
degradation was dramatically increased, and, at the same time, the system 
easily released free unmodified siRNA in reducing conditions (similar to 
those inside cancer cells with characteristic high glutathione concentration). 
PEG2000-PE micelles has gained in the last years much attention due to their 
high stability in vivo, the possibility to efficiently encapsulate poor soluble 
drugs, such as PXL (Sawant R.R. et al., 2010),  and the ability to be 
accumulate in tumors via the EPR effect. In the present work, a siRNA 
against survivin was modified with a PE moiety and then incorporated in 
nanosized PM in order to deliver the survivin siRNA in cancer cells.  
The survivin siRNA-S-S-PE was synthesized with a 90% of reaction 
yield. PM containing survivin siRNA optimized in terms of polymer 
concentration and weight ratio between polymer and survivin siRNA-S-S-
PE demonstrated a mean size of about 20 nm and a narrow size 
distribution. The survivin siRNA was efficiently incorporated in PM only 
when a higher amount of PEG2000-PE was used. In particular, the use of a 
survivin siRNA/PEG2000-PE weight ratio of 1:750 allowed reaching the 
encapsulation efficiency of about 50% (Figure 2). The hydrophobic 
interaction between the PE moiety of siRNA-S-S-PE and that of the 
PEGylated lipid serves as the driving force underlying lipid-modified 
siRNA firm incorporation into PM.  
Cell culture experiments showed a significant cytotoxic effect of 
survivin siRNA when delivered by PM. In particular, the treatment with 
survivin siRNA PM resulted in a significant decrease in cell viability in 
sensitive cancer cells and a significant down-regulation of survivin protein 
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levels, which was well in line with some previous observations (Li S.D. et 
al., 2006). It is noteworthy that in a resistant cancer cell line (SKOV3-tr), 
although little cytotoxic effect was observed, a significant down-regulation 
of survivin was still achieved following treatment with survivin siRNA 
PM. In all the cases, the treatment with the scrambled siRNA conjugate in 
PM and plain PM did not yield any noticeable effect (Figures 3 and 4). 
Thus, PM proposed in this study are able to deliver the anti-survivin siRNA 
into the cells, as demonstrated by the significant inhibition of survivin 
expression. It is important that survivin siRNA PM demonstrated a 
silencing activity even in presence of serum. Free siRNA or siRNA 
delivered by commercial transfection agents, such as Lipofectamine, has no 
activity in presence of serum (Whitehead K.A. et al., 2009). Evidently, the 
PEG shell layer of PM sterically shields the siRNA in PM from 
accessibility of serum proteins, thereby protecting it from aggregation and 
enzymatic degradation. 
As the next step, we have investigated the potential of combination 
therapy with anti-survivin siRNA and a chemotherapeutic agent, PXL. 
PXL, one of the broad spectrum anticancer agents, was selected as a model 
anticancer drug, due to its efficacy often hampered by acquiring drug 
resistance by cancer cells (Podolski-Renić A. et al., 2011). On the other 
hand, there are different lines of evidence indicating that survivin inhibition 
enhances the antitumor activity of PXL (Shen J. et al., 2013; Hu Q. et al., 
2012). With this in mind, we investigated the potential of the survivin 
down-regulation by survivin siRNA PM on the chemosensitization of 
cancer cells to PXL. With this in mind, we have studied the effect of cell 
pre-treatment survivin siRNA on the PXL chemosensitization of sensitive 
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and resistant cancer cells. In sensitive cancer cells (MDA-MB231 and 
SKOV3), the pre-treatment with survivin siRNA for 48 h before exposing 
the cells to PXL, elicited a significant improvement in the citotoxicity of 
the drug. In particular, a significant cytotoxic effect of PXL was observed 
at earlier times, namely after only 24 h of PXL treatment. In the same 
condition, but without the pre-treatment with survivin siRNA PM, PXL 
showed a cytotoxic effect only after 72 h of treatment. It is noteworthy that 
in the human paclitaxel-resistant cancer cells, SKOV3-tr, even after 72 h no 
any significant cytotoxicity was observed following treatment with PXL 
alone. The pre-treatment of SKOV3-tr  with survivin siRNA PM and the 
consequent survivin down-regulation lead to a significant cell sensitization 
to PXL (Figure 5).  
To confirm the key role of the survivin down-regulation on PXL 
sensitization in SKOV3-tr cell line, we have studied the microtubules 
organization by immunostaining the cells treated for -tubulin. Survivin 
has been shown to bind polymerized microtubules in vitro where, 
presumably, it stabilizes the mitotic spindle (Li F. et al., 1998).  Tran J. et 
al. (2002) demonstrated a role of survivin in maintaining the integrity of 
the microtubule network of a human endothelial cell (HUVECs). In 
particular, they showed that in HUVECs cells, retrovirally infected with 
wild-type survivin, the over-expression of survivin could preserve the 
microtubule integrity of the cells treated with PXL. Our results suggest that 
survivin siRNA PM mediated survivin down regulation and could 
counteract the PXL chemoresistance in SKOV3-tr cell lines (Figure 6). In 
fact, in the absence of the pre-treatment with survivin siRNA PM, no 
changes on the microtubules morphology were observed after exposure to 
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PXL. The microtubules appeared like in “healthy” cells, with elongated and 
spread out tubulin filaments. Interestingly, in survivin siRNA PM pre-
treated cells, the exposure to only 40 nM of PXL for 24 h, yielded 
significant changes in microtubules morphology. In particular, SKOV3-tr 
cells displayed a significant lack of microtubule organization reflective of 
cell death. Our data, therefore, support previous works demonstrating that 
survivin over-expression can negatively influence the sensitivity of cancer 
cell lines to chemotherapeutic agents, such as PXL.  
In a last phase of the project, we have investigated if the developed PM 
could be used for co-encapsulation of survivin siRNA and PXL in mixed 
PM, in order to deliver simultaneously the two agents in cancer cells. With 
this in mind, we have evaluated if the presence of PXL could affect the 
properties of survivin siRNA PM in terms of size distribution and survivin 
siRNA encapsulation efficiency. When PXL was added to survivin siRNA 
PM, no changes in the size and in the encapsulation efficiency was 
observed. The mixed PM co-loading the two agents demonstrated a narrow 
size distribution and an incorporation efficiency of survivin siRNA and 
PXL of about 50% and 70%, respectively. Then, we investigated the in 
vitro and then, in vivo activity of the multifunctional PM in a PXL-resistant 
ovarian cancer, SKOV3-tr. The in vitro results revealed that the 
simultaneous delivery of PXL and survivin siRNA in the cells lead to a 
significantly enhanced cytotoxicity (Figure 7). In particular, after 72 h of 
treatment with PM containing the two agents combined, a strong cytotoxic 
effect was observed. On the contrary, the treatment with free PXL did not 
elicit any significant effect. In accordance with previous findings (Shen J. 
et al., 2012) and the data observed by immunohistochemical analysis, 
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survivin inhibition can strongly influence the sensitivity of SKOV3-tr cells 
to PXL.  
Finally, the anti-tumor effect of anti-survivin siRNA and PXL co-loaded 
in PM was demonstrated in nude mice bearing SKOV3-tr tumors. The 
animals were treated with Taxol, scrambled siRNA/PXL PM, survivin 
siRNA PM and survivin siRNA/PXL PM once a week for five consecutive 
weeks at doses of 1 and 10mg/kg for PXL and siRNA, respectively. During 
the treatment, the overall health of the animals was good. No weight loss or 
evident hepatoxicity was found after repeated doses of the different PM 
formulations or even Taxol (Table III). It is worth noticing that intravenous 
injections of Taxol (PXL~ 10 mg/kg) twice a week produced significant 
body loss in SKOV-3 xenografted mice with poor improvement in the 
therapeutic outcome. 
Combination of PXL and survivin siRNA in PM resulted in sensitization 
of resistant tumors to PXL and improved anti-cancer activity. As shown in 
Figure 8A, the co-delivery of anti-survivin siRNA and PXL in PM 
inhibited tumor growth and exceeded the therapeutic effect of single 
agents. Mice treated with survivin-siRNA/PXL PM showed a 4-fold tumor 
volume reduction as compared to saline control that consistent with the 
half-reduction in tumor weight after the sacrifice of the animals. Survivin 
down-regulation by survivin siRNA PM exhibited certain anti-cancer 
activity although lesser than observed in animal treated with survivin 
siRNA/PXL-PM. This intrinsic anti-cancer activity was already described 
in SKOV3 animal model by direct tumor injection of survivin shRNA 
(Xing J. et al., 2012). Finally, the lack of therapeutic response of PXL 
either as Taxol or incorporated into scrambled siRNA/PXL PM 
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demonstrated that survivin down-regulation mediated the sensitization of 
resistant tumors to non-effective doses of PXL.  
Sequence-specific down-regulation by survivin siRNA in PM was 
confirmed in excised tumors (Figure 10).  Taxol-treated tumors had 
significant decreased levels of survivin mRNA as previously described 
(Wang Z. et al., 2005) whereas protein levels were not significantly 
decreased. Only those nanopreparations containing anti-survivin siRNA 
were able to consistently decrease survivin mRNA and protein levels at the 
same extent.  
We further characterized the tumor response to survivin siRNA and 
PXL combination by the detection of apoptosis in tumor sections. The 
degree of apoptosis (Figure 9) correlated well with the tumor growth 
curves. The highest level of tumor apoptosis was found for survivin 
siRNA/PXL PM followed by survivin siRNA PM, whereas no significant 
apoptosis increase was found for PXL formulations (Figure 9). Finally, the 
restoration of PXL sensitivity by survivin siRNA/PXL PM treatment was 
also noticed by the changes in the microtubule network in tubulin-stained 
tumor sections (Figure 12). Similar to what we observed in vitro (Salzano 
G. et al., 2014), survivin siRNA/PXL PM treatment resulted in more 
intensively stained tubulin as compared with the rest of the preparations, 
consistent with an improvement of the micro-tubule-stabilizing activity of 
PXL (Anbalagan M. et al., 2012). 
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Conclusions 
We have developed a micellar nanopreparation  (PM) containing anti-
survivin siRNA as siRNA-S-S-PE conjugate and PXL for the treatment of 
ovarian cancer. The developed system allows for easy and highly efficient 
co-encapsulation of chemotherapeutic drugs and siRNA, showed high 
colloidal stability and small particle sizes compatible with parenteral 
administration and tumor targeting. The micelles accumulate in distal 
tumors and delivered anti-survivin siRNA and PXL in sufficiently high 
amounts to mediate a potent and specific survivin down-regulation and 
improved anti-cancer activity as compared to single agents. Survivin down-
regulation by anti-survivin siRNA/PXL PM mediated the sensitization of 
the resistant ovarian tumor to non-effective doses of PXL. Finally, the 
system avoids the use of toxic excipients and is well-tolerated by the 
animals even after repeated dosing. On the whole, these results 
demonstrated that the survivin siRNA-S-S-PE PM developed in this work 
look like a promising tool to inhibit survivin expression in cancer cells. 
Moreover, due to the possibility to co-encapsulate lipophilic drugs, such as 
PXL, this system could be also used to overcome multidrug resistance in 
the treatment of chemoresistant tumors.  
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